Connective tissue disorder
MONDO:0003900A disease involving the connective tissue.
Also known as: connective tissue disease, connective tissue disease or disorder, connective tissue diseases, connective tissue disorder, connective tissue disorders, disease of connective tissue, disease or disorder of connective tissue, disease, connective tissue
4637 clinical trials for this condition and its sub-types, 70 tagged with Connective tissue disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Connective tissue disorder
-
Connective tissue neoplasm 1 trial · 2,404 incl. sub-types
13 sub-types
- Bone neoplasm 26 trials · 2,116 incl. sub-types Sub-types →
- Fibroblastic neoplasm 0 trials · 210 incl. sub-types Sub-types →
- Tumor of adipose tissue 1 trial · 98 incl. sub-types Sub-types →
- Chondrosarcoma 39 trials · 44 incl. sub-types Sub-types →
- Tenosynovial giant cell tumor 12 trials · 16 incl. sub-types Sub-types →
- Chondroma 4 trials Sub-types →
- Cholangiolocellular carcinoma 1 trial
- Solitary fibrous tumor/hemangiopericytoma 1 trial
- Angiomyxoma 0 trials
- Cartilage cancer 0 trials
- Dartoic leiomyoma 0 trials
- Lipofibromatosis-like neural tumor 0 trials
- Scirrhous adenocarcinoma 0 trials
-
Rheumatic disorder 90 trials · 1,792 incl. sub-types
30 sub-types
- Rheumatoid arthritis 576 trials · 795 incl. sub-types Sub-types →
- Lupus erythematosus 39 trials · 548 incl. sub-types Sub-types →
- Scleroderma 47 trials · 305 incl. sub-types Sub-types →
- Autoinflammatory syndrome 21 trials · 207 incl. sub-types Sub-types →
- Juvenile idiopathic arthritis 107 trials · 115 incl. sub-types Sub-types →
- Dermatomyositis 81 trials · 100 incl. sub-types Sub-types →
- Polymyalgia rheumatica 30 trials
- Rheumatic fever 16 trials
- Mixed connective tissue disease 15 trials
- Reactive arthritis 6 trials
- Camptodactyly-arthropathy-coxa vara-pericarditis syndrome 4 trials
- Gorham-Stout disease 2 trials
- Sweet syndrome 2 trials
- Palindromic rheumatism 1 trial
- Rheumatic disease of mitral valve 1 trial
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- LAMA5-related multisystemic syndrome 0 trials
- Reye syndrome 0 trials
- Wissler syndrome 0 trials
- Acroosteolysis dominant type 0 trials
- Chondrocalcinosis 2 0 trials
- Fibroblastic rheumatism 0 trials
- Idiopathic juvenile osteoporosis 0 trials
- Intermittent hydrarthrosis 0 trials
- Interstitial granulomatous dermatitis with arthritis 0 trials
- Isolated sternocostoclavicular hyperostosis 0 trials
- Myalgia-eosinophilia syndrome associated with tryptophan 0 trials
- Progeria-associated arthropathy 0 trials
- Rheumatic pulmonary valve disease 0 trials
- Unexplained long-lasting fever/inflammatory syndrome 0 trials
-
Hereditary disorder of connective tissue 0 trials · 1,311 incl. sub-types
88 sub-types
- Systemic lupus erythematosus 516 trials · 522 incl. sub-types Sub-types →
- Chronic myelogenous leukemia, BCR-ABL1 positive 211 trials · 253 incl. sub-types Sub-types →
- Uterine corpus leiomyoma 104 trials · 109 incl. sub-types Sub-types →
- Acquired polycythemia vera 90 trials
- Chondrosarcoma 39 trials · 44 incl. sub-types Sub-types →
- Type 2 collagenopathy 0 trials · 39 incl. sub-types Sub-types →
- CHILD syndrome 37 trials
- Desmoid tumor 36 trials Sub-types →
- Familial isolated pituitary adenoma 1 trial · 31 incl. sub-types Sub-types →
- Inherited acute myeloid leukemia 1 trial · 25 incl. sub-types Sub-types →
- Hereditary periodic fever syndrome 5 trials · 24 incl. sub-types Sub-types →
- Marfan and Marfan-related disorder 1 trial · 22 incl. sub-types Sub-types →
- VEXAS syndrome 18 trials
- Hypermobility spectrum disorder 16 trials
- Peyronie disease 12 trials
- Aicardi-Goutieres syndrome 9 trials Sub-types →
- Autosomal recessive inherited pseudoxanthoma elasticum 7 trials
- Ewing sarcoma of bone 5 trials
- TREX1-related type 1 interferonopathy 0 trials · 5 incl. sub-types Sub-types →
- Camptodactyly-arthropathy-coxa vara-pericarditis syndrome 4 trials
- Chronic recurrent multifocal osteomyelitis 3 trials · 4 incl. sub-types Sub-types →
- Blau syndrome 3 trials
- Ollier disease 3 trials
- Autoimmune interstitial lung disease-arthritis syndrome 3 trials Sub-types →
- Deficiency of adenosine deaminase 2 3 trials
- Hereditary multiple osteochondromas 3 trials Sub-types →
- Inherited torticollis 3 trials
- Maffucci syndrome 2 trials
- STING-associated vasculopathy with onset in infancy 2 trials
- Familial chilblain lupus 2 trials Sub-types →
- Proteosome-associated autoinflammatory syndrome 2 trials Sub-types →
- Sweet syndrome 2 trials
- ADAR-related type 1 interferonopathy 0 trials · 1 incl. sub-types Sub-types →
- Singleton-Merten dysplasia 1 trial Sub-types →
- Arterial tortuosity syndrome 1 trial
- Cherubism 1 trial Sub-types →
- Hyperparathyroidism 2 with jaw tumors 1 trial
- Infantile myofibromatosis 1 trial Sub-types →
- Neonatal severe primary hyperparathyroidism 1 trial
- Ossification of the posterior longitudinal ligament of the spine 1 trial
- EMILIN-1-related connective tissue disease 0 trials
- Ehlers-Danlos syndrome, kyphoscoliotic type 1 0 trials
- IFIH1-related type 1 interferonopathy 0 trials Sub-types →
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- LAMA5-related multisystemic syndrome 0 trials
- MASS syndrome 0 trials
- Pelger-Huet-like anomaly and episodic fever with abdominal pain 0 trials
- RNASEH2A-related type 1 interferonopathy 0 trials Sub-types →
- RNASEH2B-related type 1 interferonopathy 0 trials Sub-types →
- RNASEH2C-related type 1 interferonopathy 0 trials Sub-types →
- RNU7-1-related type 1 interferonopathy 0 trials Sub-types →
- SAMHD1-related type 1 interferonopathy 0 trials Sub-types →
- Sharpin-related autoinflammatory syndrome 0 trials
- Spondyloenchondrodysplasia with immune dysregulation 0 trials
- X-linked reticulate pigmentary disorder 0 trials
- Acroosteolysis dominant type 0 trials
- Aneurysmal bone cyst 0 trials
- Arterial tortuosity-bone fragility syndrome 0 trials
- Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation 0 trials
- Autoinflammatory disease, X-linked 0 trials
- Autoinflammatory disease, multisystem, with immune dysregulation, X-linked 0 trials Sub-types →
- Autoinflammatory disease, systemic, with vasculitis 0 trials
- Autoinflammatory syndrome with immunodeficiency 0 trials
- Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis 0 trials
- Autoinflammatory syndrome, familial, Behcet-like 0 trials Sub-types →
- Bone fragility with contractures, arterial rupture, and deafness 0 trials
- Brittle cornea syndrome 0 trials Sub-types →
- Chondrocalcinosis 2 0 trials
- Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome 0 trials
- Diaphyseal medullary stenosis-bone malignancy syndrome 0 trials
- Encephalocraniocutaneous lipomatosis 0 trials
- Familial ossifying fibroma 0 trials
- Hyperparathyroidism 1 0 trials
- Hyperparathyroidism 3 0 trials
- Hyperparathyroidism 4 0 trials
- Idiopathic juvenile osteoporosis 0 trials
- Jugulotympanic paraganglioma 0 trials Sub-types →
- Juvenile hyaline fibromatosis 0 trials
- Linkeropathy 0 trials Sub-types →
- Multiple epiphyseal dysplasia due to collagen 9 anomaly 0 trials Sub-types →
- Multiple symmetric lipomatosis 0 trials Sub-types →
- Neonatal inflammatory skin and bowel disease 0 trials Sub-types →
- Progeroid and marfanoid aspect-lipodystrophy syndrome 0 trials
- Pseudo-TORCH syndrome 2 0 trials
- Psoriasis 14, pustular 0 trials
- Pyogenic arthritis-pyoderma gangrenosum-acne syndrome 0 trials
- Thrombocytopenia 6 0 trials
- Trichohepatoenteric syndrome 0 trials Sub-types →
-
Disease of the tendon 126 trials · 192 incl. sub-types
3 sub-types
- Tendinitis 24 trials · 77 incl. sub-types Sub-types →
- Tendon sheath disorder 0 trials · 30 incl. sub-types Sub-types →
- Tendinosis 17 trials
-
Benign connective and soft tissue neoplasm 0 trials · 101 incl. sub-types
5 sub-types
- Bone benign neoplasm 1 trial · 70 incl. sub-types Sub-types →
- Benign soft tissue neoplasm 0 trials · 16 incl. sub-types Sub-types →
- Benign lipomatous neoplasm 0 trials · 15 incl. sub-types Sub-types →
- Benign osteogenic neoplasm 0 trials Sub-types →
- Lipofibromatosis 0 trials
-
Fasciitis 7 trials · 97 incl. sub-types
6 sub-types
- Plantar fasciitis 85 trials
- Necrotizing fasciitis 7 trials
- Eosinophilic fasciitis 1 trial
- Ischemic fasciitis 0 trials
- Nodular fasciitis 0 trials Sub-types →
- Proliferative fasciitis 0 trials
-
Collagenopathy 3 trials · 42 incl. sub-types
3 sub-types
- Type 2 collagenopathy 0 trials · 39 incl. sub-types Sub-types →
- Disseminated eosinophilic collagen disease 0 trials
- Multiple epiphyseal dysplasia due to collagen 9 anomaly 0 trials Sub-types →
-
Interstitial cystitis 39 trials
-
Periostitis 0 trials · 16 incl. sub-types
2 sub-types
- Alveolar periostitis 16 trials
- Orbital periostitis 0 trials
-
Synovitis 15 trials
1 sub-type
- Gonococcal synovitis 0 trials
-
Overlapping connective tissue disease 2 trials · 15 incl. sub-types
2 sub-types
- Mixed connective tissue disease 15 trials
- MASS syndrome 0 trials
-
Panniculitis 3 trials · 6 incl. sub-types
6 sub-types
- Lipodermatosclerosis 1 trial
- Nodular non-suppurative panniculitis 1 trial
- Panniculitis and localized lipodystrophy 1 trial
- Cytophagic histiocytic panniculitis 0 trials
- Erythema nodosum 0 trials
- Lupus erythematosus panniculitis 0 trials
-
Enthesopathy 2 trials · 4 incl. sub-types
5 sub-types
- Enthesitis 2 trials
- Fibular collateral ligament bursitis 0 trials
- Olecranon bursitis 0 trials
- Pes anserinus tendinitis or bursitis 0 trials
- Tibial collateral ligament bursitis 0 trials
-
Ochronosis disorder 1 trial
1 sub-type
- Exogenous ochronosis 0 trials
-
Ainhum 0 trials
-
Interstitial keratitis 0 trials
1 sub-type
- Diffuse interstitial keratitis 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 956 trials in this tab.
-
Can a calming drug make cord blood transplants safer?
Cure PausedResearchers are testing whether adding abatacept to standard immune-suppressing drugs can prevent severe graft-versus-host disease after a double umbilical cord blood transplant. The trial enrolls people with blood cancers such as leukemia, lymphoma, and myelodysplastic syndromes…
Phase 2 • Sponsor: Leland Metheny • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
Cure OngoingThis early-stage trial is testing an experimental cell therapy for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to recognize …
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
New cocktail of drugs aimed at halting bone metastases in prostate cancer
Disease control PausedThis study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Real-World lupus drug study launches in poland
Disease control OngoingThis study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall response over time. The goal is to see how well the drug works outside of contr…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Radioactive Bone-Seeking drug paired with chemo shows promise for advanced breast cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and see if it can slow or stop cancer growth. Researchers will also track how long patients live …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims to deepen remission in early CML
Disease control OngoingThis study tests whether adding ASTX727 to the standard drug dasatinib can better control chronic myeloid leukemia (CML) in newly diagnosed patients. About 70 adults with a specific genetic marker (Philadelphia chromosome) will receive both pills. The goal is to see if the combin…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug duo targets hard-to-treat blood cancers
Disease control OngoingThis study tests a new drug, seclidemstat, combined with a standard drug, azacitidine, for people with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to find the best dose and see if the combination can shrink or control the cancer. About 2…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in large trial
Disease control By invitation onlyThis study is checking the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). It involves 760 participants who have already completed earlier studies of the drug. Researchers will monitor side effects over time to see if th…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingThis study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…
Phase 2/3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo aims to wipe out lingering leukemia before transplant
Disease control OngoingThis phase 2 trial tests whether a combination of venetoclax and azacitidine can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who still have or develop leftover cancer cells after initial chemotherapy, and before a stem cell transplant. Abou…
Phase 2 • Sponsor: Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Gene therapy shot aims to tame autoimmune diseases in early trial
Disease control OngoingThis early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…
Early phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill hopes to boost blood in bone marrow disease
Disease control OngoingThis study tests an experimental drug, HT-6184, in adults with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). The goal is to see if the drug can improve blood counts and reduce the need for transfusions. Participants take…
Phase 2 • Sponsor: Halia Therapeutics, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New study tests everolimus for kidney tumors in TSC patients
Disease control OngoingThis study looks at how safe and effective the drug everolimus is for Taiwanese adults with tuberous sclerosis complex (TSC) who have kidney tumors called angiomyolipomas. Four participants will take the drug and be monitored for side effects and tumor shrinkage. The goal is to c…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Cancer drug RVU120 gets extended trial for ongoing patients
Disease control By invitation onlyThis study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Virus plus radiation may shrink sarcomas before surgery
Disease control OngoingThis study tests whether a cancer-killing virus (T-VEC) combined with radiation can shrink soft tissue sarcomas before surgery. About 40 adults with newly diagnosed, removable sarcomas will receive the virus injected into the tumor plus radiation. The main goals are to see how ma…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to stall rare Cancer's spread
Disease control OngoingThis study compares the drug palbociclib alone versus palbociclib plus cemiplimab in 77 people with advanced dedifferentiated liposarcoma that cannot be removed by surgery. Palbociclib blocks enzymes that help cancer cells grow, while cemiplimab boosts the immune system to attack…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hip implant aims to fix cartilage without replacement
Disease control OngoingThis early study is testing a new device called the ReNew Hip Implant in 15 people aged 14 to 64 with hip cartilage damage from conditions like osteoarthritis or hip impingement. The implant is surgically placed to repair the cartilage. Researchers are checking if it is safe and …
Sponsor: Cytex Therapeutics, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can an HDAC inhibitor wipe out residual leukemia cells?
Disease control OngoingResearchers are studying whether the drug chidamide can help keep high-risk acute myeloid leukemia (AML) in remission when used as maintenance therapy. The trial enrolls adults with specific genetic features and measurable residual disease who are not receiving a stem cell transp…
Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Experimental drug TAK-243 targets tough blood cancers in early trial
Disease control OngoingThis early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for older leukemia patients with gentler drug combo
Disease control OngoingThis study tests a new two-drug combination (ASTX727 and venetoclax) in adults with acute myeloid leukemia who are 75 or older, or have health issues that make standard strong chemotherapy too risky. The goal is to see if the drugs work well together and can control the leukemia.…
Phase 1/2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Immune cell therapy takes on tough scleroderma
Disease control OngoingThis early trial tests whether a single infusion of anti-CD19 CAR T-cells can improve skin thickening and other symptoms in 6 adults with severe, treatment-resistant systemic sclerosis. Participants receive chemotherapy before the infusion and are monitored for 24 months. The stu…
Phase 2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Hard-to-Treat leukemia: targeted pill combined with chemotherapy enters human trials
Disease control OngoingThis early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…
Phase 1 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Immunotherapy boost may wipe out stubborn leukemia cells
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard tyrosine kinase inhibitors (TKIs) can eliminate tiny amounts of leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with CML who still have detectable cancer marker…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for rare inflammatory disease: pacritinib trial begins
Disease control OngoingThis study tests a drug called pacritinib for people with VEXAS syndrome, a rare genetic disease that causes severe inflammation. About 78 adults will receive either the drug or a placebo to see if it controls symptoms and reduces flare-ups. The goal is to find a safe and effecti…
Phase 2 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill shows promise for rare tumor in japanese patients
Disease control OngoingThis phase 2 study tests the drug nirogacestat in 20 Japanese adults with desmoid tumors that are growing. The goal is to see if the drug can shrink tumors or stop them from getting worse. Participants take nirogacestat as an oral tablet, and researchers will monitor tumor respon…
Phase 2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill could tame lupus flares in major trial
Disease control OngoingThis phase 3 trial tests whether adding cenerimod, a daily pill, to standard lupus treatments can reduce symptoms in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo for 12 months. Researchers wil…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill aims to tame rare immune diseases
Disease control OngoingThis early-stage trial tests an experimental drug called BI 3000202 in 16 adults with rare type 1 interferonopathies, such as Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the drug is safe and how…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis Phase 3 study tests whether adding cenerimod to standard lupus treatments can better control moderate-to-severe lupus symptoms. About 451 adults will receive either cenerimod or a placebo for 12 months. The main goal is to see if more people improve on a lupus disease activi…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Engineered donor cells aim to beat blood cancer without severe side effects
Disease control OngoingThis study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Immunotherapy combo shows promise against rare sarcomas before surgery
Disease control OngoingThis study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) and radiation before surgery can help shrink tumors in people with two rare types of sarcoma. About 32 adults with these cancers that can be surgically removed will receive the treatment an…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise in controlling Early-Stage leukemia
Disease control OngoingThis study tests a combination of two drugs, dasatinib and venetoclax, in people with early chronic phase chronic myeloid leukemia (CML). The goal is to see if the combination can better control the disease by blocking enzymes that help cancer cells grow. About 155 participants w…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo therapy shows promise for rare cancer
Disease control OngoingThis study tests whether combining two drugs, palbociclib and INCMGA00012, is safe and effective for people with advanced liposarcoma, a rare cancer of fat cells. About 42 participants with tumors that cannot be removed by surgery or have spread will receive the combination. The …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could a daily ultrasound zap arthritis pain at home?
Disease control OngoingThis study tests a non-invasive device that uses ultrasound to stimulate the spleen and reduce inflammation in people with moderate to severe rheumatoid arthritis. About 60 adults who haven't responded well to standard medications will use the device at home for 12 weeks, with so…
Sponsor: SecondWave Systems Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail aims to stop leukemia relapse after transplant
Disease control OngoingThis phase 2 trial tests whether combining venetoclax and azacitidine after a stem cell transplant can prevent leukemia from returning in high-risk patients. About 100 adults aged 18-75 with certain types of acute leukemia who are in remission after transplant will receive the dr…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental CART123 therapy targets tough blood cancers in early trial
Disease control OngoingThis early-phase trial tests a personalized cell therapy called CART123 for people with certain blood cancers (like AML or MDS) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to recognize and attack cancer cells. The main goa…
Early phase 1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a Patient's own blood beat a standard dressing for dry socket?
Disease control OngoingThis trial tests two treatments for dry socket, a painful complication after tooth extraction. One is Alvogyl, a standard medicated dressing. The other is platelet-rich fibrin (PRF), made from the patient's own blood, which may help tissue heal. About 102 adults with dry socket w…
Sponsor: CMH Lahore Medical College and Institute of Dentistry • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Blood cancer combo trial pulled before it even started
Disease control CancelledThis study was designed to test whether adding olutasidenib to standard chemotherapy drugs could help control certain blood cancers in people with an IDH1 gene mutation. The trial was withdrawn before enrolling any participants, so no results are available.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in 680 patients
Disease control By invitation onlyThis study looks at the long-term safety of cenerimod in adults with moderate-to-severe lupus. About 680 participants who were in a previous study will take cenerimod for up to 3 years, along with their usual lupus medications. Researchers will track side effects and see how well…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
Disease control CancelledThis phase 2 trial is testing whether combining an experimental drug called S-531011 with a precise radiation technique known as RadScopal can help control metastatic colorectal cancer that has not responded to prior treatments. The study enrolls about 30 adults with advanced dis…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an oral drug calm psoriatic arthritis? phase 3 trial puts deucravacitinib to the test
Disease control OngoingResearchers are testing whether deucravacitinib, a daily oral drug, can reduce joint swelling, tenderness, and skin symptoms in people with active psoriatic arthritis. The trial enrolls adults who have not taken biologic drugs for their arthritis or who previously received a TNF …
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New cocktail of cancer drugs tested for tough leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs — bortezomib, sorafenib, and decitabine — in patients with acute myeloid leukemia (AML), especially those who are older or have hard-to-treat forms. The main goal is to find the safest dose and see how well patients tolera…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New triple therapy targets FLT3-Mutated leukemia in frail patients
Disease control OngoingThis study tests a combination of three drugs—gilteritinib, venetoclax, and azacitidine—in people newly diagnosed with a fast-growing form of acute myeloid leukemia (AML) that has a FLT3 gene change. Participants are older or have other health issues that prevent them from receiv…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New lupus drug shows promise in Long-Term safety trial
Disease control By invitation onlyThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug DFV890 takes on Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new drug called DFV890 in about 62 adults with low-risk myelodysplastic syndromes, low-risk chronic myelomonocytic leukemia, or high-risk clonal cytopenia of undetermined significance. The main goals are to check the drug's safety, find the best dos…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a new drug trio overcome venetoclax resistance in leukemia?
Disease control By invitation onlyResearchers are testing whether a combination of homoharringtonine, lisaftoclax, and azacitidine can help adults with acute myeloid leukemia (AML) whose disease stopped responding to venetoclax-based treatment. The trial plans to enroll 73 participants and give them the three dru…
Phase 2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug aims to tame scleroderma in major trial
Disease control OngoingThis Phase 3 study tests whether anifrolumab, given as a weekly shot, can improve symptoms of systemic sclerosis (scleroderma) compared to a placebo. About 314 adults aged 18-70 with early-stage disease will take part. The main goal is to see if more people respond to treatment, …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could a cancer drug help patients with rare gene changes?
Disease control OngoingThis phase 2 trial tests the drug olaparib in 14 adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to treatment, and whose cancer has a specific change in the IDH gene. Olaparib is a pill that may block enzymes cancer cells need to …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New cell therapy aims to stop blood cancer relapse in tough-to-treat patients
Disease control CancelledThis early-phase study tests a new cell therapy called BSB-2002 in adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to at least two prior treatments. The main goals are to check safety and see if it can prevent the cancer from coming …
Phase 1 • Sponsor: BlueSphere Bio, Inc • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could dead donors provide Life-Saving bone marrow?
Disease control OngoingThis early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…
Phase 1/2 • Sponsor: Ossium Health, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New injection aims to tame lupus when standard treatments fail
Disease control OngoingThis early-stage study tests an injection called GC012F in 20 adults with refractory systemic lupus erythematosus (SLE) — a type of lupus that hasn't responded to standard treatments. The goal is to see if the therapy is safe and can reduce disease activity. Participants receive …
Phase 1/2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for rare leukemia: Anthracycline-Free combo trial launches
Disease control OngoingThis study tests a combination of drugs (venetoclax plus azacitidine, decitabine, or cytarabine) without traditional anthracycline chemotherapy in 40 adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CBFβ::MYH11-positive). The goal is to see if thi…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Experimental combo aims to outsmart relapsed blood cancers
Disease control OngoingThis early-stage trial tests whether adding the immunotherapy drug ipilimumab to the chemotherapy drug decitabine is safe and tolerable for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back or stopped responding to treatment. About 54 p…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New arthritis drug shows promise in Long-Term safety trial
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. About 1560 adults who finished an earlier study will receive the drug as a shot under the skin. Researchers will track side effects and how well the drug c…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can adding another drug improve MDS treatment?
Disease control OngoingThis study compares the standard drug azacitidine alone versus azacitidine combined with either lenalidomide or vorinostat in 282 patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if any combination improves re…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo targets tough blood cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called SEA-CD70, alone or with standard drugs azacitidine and venetoclax, in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goal is to check safety and find the right dose. About 178 participants will b…
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill combo aims to tame bone marrow cancer
Disease control OngoingThis early-phase study tests whether adding a new drug called pelabresib to the standard treatment ruxolitinib is safe and helpful for Japanese adults with myelofibrosis, a type of bone marrow cancer. Only 6 people will take part, and the main goal is to check for side effects an…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug cocktail targets rare bone cancer that spreads
Disease control OngoingThis study tests two drug combinations (belinostat plus either guadecitabine or ASTX727) in 19 adults with a rare bone cancer called chondrosarcoma that has spread or cannot be removed surgically. The goal is to see if the drugs can shrink tumors or stop them from growing. Partic…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Engineered immune cells take on rare autoimmune disease in kids
Disease control PausedThis early-stage trial tests whether a type of immunotherapy called CAR-T cells can safely treat children with severe systemic sclerosis, a rare autoimmune disease that causes skin thickening and organ damage. The treatment involves collecting the child's own immune cells, engine…
Phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a targeted drug boost chemo for osteosarcoma?
Disease control PausedThis trial is testing whether adding the targeted drug cabozantinib to standard chemotherapy (methotrexate, doxorubicin, and cisplatin) helps people with newly diagnosed osteosarcoma, a type of bone cancer. The study includes over 1,100 participants and aims to see if the combina…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Promising drug cocktail targets tough blood cancers
Disease control OngoingThis study tests a combination of two drugs, venetoclax and ASTX727, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who haven't had treatment before. The goal is to find the safest dose and see if the combo can shrink or control …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Targeted drug shows promise for rare bone cancer
Disease control OngoingThis phase 2 trial is testing whether cetuximab, a targeted antibody drug, can shrink tumors in people with advanced or metastatic chordoma, a rare type of bone cancer. About 29 adults with inoperable or spread chordoma will receive cetuximab intravenously. The main goal is to se…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Lupus drug anifrolumab put to the test in Real-World study
Disease control OngoingThis study follows 551 people with lupus who are starting anifrolumab for the first time. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over time. The goal is to see if the benefits seen in clinical trials hold up…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a targeted drug hit the mark in Hard-to-Treat blood cancers?
Disease control OngoingThis trial tests an experimental drug called IMGN632 in people with certain blood cancers, including acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. The drug is designed to find and attack cancer cells that carry a protein called CD123 on their surface. R…
Phase 1/2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Immune cell reprogramming offers hope for stubborn arthritis and Sjogren's
Disease control OngoingThis early-phase study tests a personalized cell therapy (rapcabtagene autoleucel) in 27 adults with difficult-to-treat rheumatoid arthritis or severe Sjogren's disease. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system. The…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo offers hope for older AML patients who Can't tolerate chemo
Disease control OngoingThis study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in two groups: patients whose cancer returned or didn't respond to prior treatment, and older adults newly diagnosed who cannot handle strong chemotherapy. The drugs work toge…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a Two-Drug combo in one liposome beat AML at first try?
Disease control OngoingThis pilot trial tests whether Vyxeos, a liposomal formulation combining two chemotherapy drugs, can effectively treat newly diagnosed low- or intermediate-risk acute myeloid leukemia (AML) in adults aged 18 to 70. Some participants also receive Mylotarg, an antibody-drug conjuga…
Phase 2 • Sponsor: Shaare Zedek Medical Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New lupus drug RO7507062 enters first human safety trial
Disease control OngoingThis early-stage study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin, and the study will look for side effects and …
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug GS-0151 tested for rheumatoid arthritis in early trial
Disease control OngoingThis early-stage trial is testing a new drug called GS-0151 in 75 adults with rheumatoid arthritis. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either GS-0151 or a placebo for 12 weeks.
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could removing certain immune cells prevent a deadly transplant complication?
Disease control OngoingThis study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell tr…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a lower dose of a leukemia drug keep the disease in check?
Disease control OngoingThis study tests whether reducing the dose of the cancer drug radotinib can still control chronic myeloid leukemia in its early phase while possibly easing side effects. Adults newly diagnosed with this blood cancer take a lower dose twice daily for up to a year. Researchers meas…
Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a newer drug outperform the standard for chronic myeloid leukemia?
Disease control OngoingThis phase III trial compares two oral drugs, radotinib and imatinib, in adults newly diagnosed with chronic myeloid leukemia in its chronic phase. Researchers want to see if radotinib, taken twice daily, achieves a deeper molecular response at 12 months than imatinib, taken once…
Phase 3 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new knee implant design offer better Long-Term relief?
Disease control By invitation onlyThis study tests a new total knee replacement system called LinkSymphoKnee, which uses an ultra-congruent bearing surface designed to provide stability and mimic natural knee movement. Researchers will enroll 600 adults aged 18 to 79 who need a knee replacement due to osteoarthri…
Sponsor: LinkBio Corp. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug CND261 tested for rheumatoid arthritis relief
Disease control OngoingThis early-stage study tests a new drug, CND261, in 47 adults with moderate to severe rheumatoid arthritis who haven't responded well to other treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that it might…
Phase 1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug hope for scleroderma patients with lung complications
Disease control OngoingThis study tests an experimental drug called ifetroban in 34 adults with a severe form of scleroderma (diffuse cutaneous systemic sclerosis) or scleroderma-related lung disease (pulmonary arterial hypertension). The main goal is to see if the drug is safe and whether it can impro…
Phase 2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a drug combo boost red blood cells in bone marrow disease?
Disease control OngoingThis phase 3 trial compares two treatments for people with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). One group gets lenalidomide alone, the other gets lenalidomide plus epoetin alfa, a drug that stimulates red blood …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can an enzyme blocker boost leukemia chemotherapy?
Disease control OngoingThis phase 1 trial tests whether adding the experimental drug calaspargase pegol-mknl to standard chemotherapy can safely help adults with newly diagnosed acute myeloid leukemia (AML). Researchers aim to find the highest tolerable dose and watch for side effects. They will also t…
Phase 1 • Sponsor: West Virginia University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hip implant aims to cut repeat surgeries
Disease control OngoingThis study is testing a new hip implant called the OR3O Dual Mobility System in 177 people who need hip replacement surgery. The goal is to see if the implant is safe and lasts longer without needing another surgery. Researchers will follow participants for up to 10 years to chec…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
One-Time cell therapy could tame tough lupus
Disease control OngoingThis study tests a one-time treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with active lupus or lupus kidney disease that hasn't improved with standard therapies. About 179 adults will receive the treatment after a short chemotherapy …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Double whammy for AFib: single procedure aims to fix rhythm and prevent strokes
Disease control OngoingThis study tests doing two heart procedures at the same time for people with atrial fibrillation. First, doctors use pulsed field energy to fix the heart's rhythm. Then, they implant a small device to close off a part of the heart where clots can form. The goal is to see if this …
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
One-Time cell therapy aims to tame tough scleroderma
Disease control OngoingThis study tests a new treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with severe scleroderma that hasn't improved with standard care. About 96 participants will receive either this one-time cell therapy or the current drug rituximab.…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Precision radiation may make stem cell transplants safer for leukemia patients
Disease control OngoingThis study tests a new way to deliver radiation before a stem cell transplant for people with leukemia or myelodysplastic syndrome. Instead of radiating the whole body, the new method targets only the bone marrow and lymph nodes, which may reduce damage to healthy organs. The goa…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for rare blood disorder: drug targets overactive immune cells
Disease control OngoingThis phase 2 trial is testing the drug ruxolitinib in people with hypereosinophilic syndrome, a rare condition where the body produces too many eosinophils (a type of white blood cell), causing organ damage. The study aims to see if ruxolitinib can normalize blood cell counts and…
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can Blood-Based injections realign the jaw joint?
Disease control OngoingThis trial compares two injection treatments for a common jaw joint problem where the disc slips out of place but returns, causing pain and clicking. One treatment uses a concentrate from the patient's own blood, called platelet-rich fibrin, while the other uses a sugar solution.…
Phase 2 • Sponsor: Cairo University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New study tests belimumab to tame early lupus
Disease control OngoingThis study is testing the drug belimumab (Benlysta) in 350 adults who were diagnosed with systemic lupus erythematosus (SLE) within the last two years and still have active disease despite standard treatment. The goal is to see if adding belimumab helps more people reach a state …
Phase 4 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo therapy shows promise for tough kidney cancer
Disease control OngoingThis study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New CML pill shows promise in Head-to-Head trial against standard treatments
Disease control OngoingThis study tests a new daily pill, asciminib, against several standard drugs for people newly diagnosed with a type of leukemia called CML. About 405 adults will be randomly assigned to receive either asciminib or a standard tyrosine kinase inhibitor (TKI). The main goal is to se…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a new pill calm psoriatic arthritis joint pain?
Disease control OngoingThis phase 3 trial tests whether an experimental drug called SHR0302 can reduce joint pain and swelling in people with active psoriatic arthritis, a condition that combines joint inflammation with psoriasis. About 418 adults with at least six months of symptoms and active joint d…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New biologic shot aims to stop psoriatic arthritis joint damage
Disease control OngoingThis phase 3 trial tested guselkumab, a biologic drug given as a shot, in over 1,000 people with active psoriatic arthritis who had not responded well to other treatments. The goal was to see if it reduces symptoms like joint pain and swelling and slows joint damage seen on X-ray…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for spine pain in psoriatic arthritis: guselkumab under study
Disease control OngoingThis phase 4 trial tests whether guselkumab (TREMFYA) can reduce spine-related symptoms in people with active psoriatic arthritis who have not used biologic drugs before. About 411 participants will receive either guselkumab or a placebo as a shot under the skin. The main goal is…
Phase 4 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Cancer drug safety tracked in ongoing rollover trial
Disease control By invitation onlyThis study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for tough blood cancers? early trial of JNJ-89853413 begins
Disease control OngoingThis early-stage trial tests a new drug called JNJ-89853413 in 64 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, with a second part looking a…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New shoulder implant tested for long-term relief in severe tears and arthritis
Disease control OngoingThis study follows 200 adults who receive the Shoulder iD™ implant to treat severe rotator cuff tears or shoulder arthritis. Researchers measure how well the shoulder works and how often the implant needs to be fixed or replaced over 10 years. Participants attend regular check-up…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a diet calm inflamed joints in children with arthritis?
Disease control OngoingResearchers are testing whether a specific carbohydrate diet, which has anti-inflammatory effects in children with inflammatory bowel disease, can also reduce joint inflammation in children with juvenile idiopathic arthritis. The trial includes children up to age 16 with low to m…
Sponsor: Uppsala University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a replacement enzyme keep calcium buildup in check?
Disease control OngoingThis trial tests the long-term safety of a drug called INZ-701 in people with rare genetic conditions that cause abnormal calcium buildup in the body. The study enrolls people who have already received INZ-701 in an earlier trial and want to continue treatment. Researchers will m…
Phase 2 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy targets tough leukemia mutations
Disease control OngoingThis early-stage study tests a new drug called bleximenib combined with other leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 partici…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New radioactive drug aims to hit bone tumors while sparing marrow
Disease control CancelledThis early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill could ease joint pain for psoriatic arthritis patients
Disease control OngoingThis study tests an experimental drug called JNJ-77242113 (icotrokinra) against a placebo in 552 adults with active psoriatic arthritis who have not tried biologic treatments before. The main goal is to see if the drug reduces joint swelling and tenderness after 16 weeks. Partici…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Children with Crohn's, colitis, or psoriatic arthritis get long-term safety check on stelara
Disease control OngoingThis study follows 159 children aged 2 to 17 who have already completed a prior ustekinumab study for Crohn's disease, ulcerative colitis, or psoriatic arthritis. The goal is to collect long-term safety data by monitoring side effects, lab results, and injection-site reactions. P…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New ankle implant tracked for 10 years in 500 arthritis patients
Disease control OngoingThis study follows 500 people who received the INFINITY total ankle replacement to see how well the implant holds up over 10 years. Participants have ankle arthritis from rheumatoid arthritis, injury, or wear-and-tear. Researchers will measure implant survival and changes in pain…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New shot could tame lupus skin flares
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in people with lupus-related skin rashes (subacute or chronic cutaneous lupus) that haven't gotten better with standard treatments. About 56 participants will receive either the drug or a placebo for 12 weeks, then all get th…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a new drug overcome a tough leukemia mutation?
Disease control OngoingThis trial tests whether asciminib, a drug taken twice daily, can reduce leukemia burden in people with chronic phase chronic myeloid leukemia (CML) who have a specific T315I mutation. The study enrolls 50 adults in Germany, including those who had a stem cell transplant. The mai…
Phase 2 • Sponsor: Thomas Ernst, PD Dr. med. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a nerve stimulator calm rheumatoid arthritis?
Disease control OngoingThis study tests whether an implantable vagus nerve stimulation device can safely reduce symptoms of rheumatoid arthritis in adults who have not gotten enough relief from at least two biologic or targeted synthetic DMARDs. Participants receive the device, which sends electrical p…
Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can less be more? new study tests lower drug dose to keep leukemia at bay
Disease control OngoingThis study tests whether a lower dose of the drug venetoclax can be safely given to adults with acute myeloid leukemia (AML) who are already in remission. The goal is to reduce severe side effects like low white blood cell counts while still preventing the cancer from coming back…
Phase 2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new drug regimen beat the standard for stem cell transplant complications?
Disease control OngoingThis trial tests whether a drug called cyclophosphamide (PTCY) can prevent graft-versus-host disease (GVHD) better than the current standard, ATG, in patients receiving stem cell transplants from unrelated donors. GVHD is a serious complication where donor immune cells attack the…
Phase 3 • Sponsor: DKMS gemeinnützige GmbH • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New radiation technique may make stem cell transplants safer for scleroderma patients
Disease control OngoingThis early study tests whether a precise type of total body radiation (IMRT) combined with chemotherapy can safely prepare the body for a stem cell transplant in people with severe systemic sclerosis (scleroderma). The goal is to reduce radiation exposure to the lungs and kidneys…
Early phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New chemo combo aims to stop leukemia return after transplant
Disease control OngoingThis phase 2 trial tests giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant in 72 patients with leukemia or myelodysplastic syndrome in remission. The goal is to prevent the cancer from coming back after the transplant while causing fewe…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New pill could tame rare blood disorder without chemotherapy
Disease control OngoingThis phase 3 trial compares bomedemstat, an experimental oral drug, to hydroxyurea (standard therapy) in 300 people with essential thrombocythemia who have not yet received cytoreductive treatment. The goal is to see if bomedemstat better controls platelet counts and prevents com…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New CML drug shows better tolerability in Head-to-Head trial
Disease control OngoingThis study tests whether asciminib is easier to tolerate than nilotinib in adults newly diagnosed with a type of leukemia called Philadelphia chromosome-positive CML. About 568 participants take either asciminib once daily or nilotinib twice daily. The main goal is to see how lon…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for patients with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has returned or not responded to treatment. Researchers take a patient's own (or a donor's) T-cells, modify them in…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could a chemo drug help patients with rare bone marrow cancer?
Disease control OngoingThis phase II trial tests the drug decitabine in 21 patients with advanced myelofibrosis, a bone marrow cancer that causes scarring and anemia. The goal is to see if decitabine can improve blood counts and reduce the need for transfusions. Researchers are also monitoring side eff…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Injections vs. scalpel: which straightens Peyronie's curvature better?
Disease control OngoingThis trial asks whether collagenase injections (Xiaflex) or surgery is the better approach for treating Peyronie's disease, a condition that causes penile curvature and pain. About 40 men with curvature of at least 30 degrees will receive either a full course of eight Xiaflex inj…
Phase 4 • Sponsor: Charitable Union for the Research and Education of Peyronie's Disease • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New ankle implant tracked for 10 years in arthritis patients
Disease control OngoingThis study follows 200 adults with ankle arthritis who received the INFINITY ankle replacement. Researchers will check how long the implant lasts and monitor for any problems like loosening or cysts over 10 years. The goal is to see if this device works as well as other similar i…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a Two-Drug attack outsmart resistant leukemia?
Disease control OngoingThis early-stage trial is testing whether adding an experimental drug called iadademstat to the approved leukemia drug gilteritinib can help people with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The study focuses on patients …
Phase 1 • Sponsor: Oryzon Genomics S.A. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New radiation drug shows promise for Tough-to-Treat breast cancer
Disease control OngoingThis early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to standard treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it …
Phase 1/2 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis study tests a new drug called ianalumab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 436 participants receive either ianalumab or a placebo as a shot under the skin, once a month or once every three months, along with their u…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for PMR patients: Long-Term safety trial of secukinumab underway
Disease control OngoingThis study is testing the long-term safety of secukinumab, a biologic drug, in people with polymyalgia rheumatica (PMR). It includes 161 patients who already completed a 52-week study of secukinumab and had a relapse after stopping treatment. The main goal is to see how safe and …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis phase 3 study tests whether adding a monthly injection of ianalumab to standard lupus treatments helps control active disease better than placebo. About 288 people aged 12 and older with systemic lupus erythematosus (SLE) are taking part. The main goal is to see if ianalumab…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New shot could tame lupus kidney flares
Disease control OngoingThis phase 3 trial tests whether adding ianalumab (a biologic injection) to standard therapy helps control active lupus nephritis, a serious kidney complication of lupus. About 452 adults with active lupus nephritis are receiving either ianalumab every 4 or 12 weeks or a placebo,…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Could a personalized diet tame rheumatoid arthritis and protect the heart?
Disease control By invitation onlyThis study tests whether a personalized diet, based on the latest Nordic Nutrition Recommendations, can reduce disease activity and cardiovascular risk in people newly diagnosed with rheumatoid arthritis. About 150 participants will be randomly assigned to either a diet following…
Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a drug duo keep High-Risk blood cancers at bay after transplant?
Disease control OngoingThis early-phase trial is exploring whether combining two drugs, selinexor and azacitidine, can help prevent relapse in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who carry a TP53 mutation and have already undergone a stem cell transplant…
Phase 1/2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a new infusion drug tame lung inflammation and cut steroid use?
Disease control OngoingThis trial is investigating whether an experimental drug called XTMAB-16 can safely control pulmonary sarcoidosis over the long term. The study includes people who have already completed a previous XTMAB-16 trial and are on a stable steroid dose. Researchers are monitoring side e…
Phase 2 • Sponsor: Xentria, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Green tea extract may boost fertility in women with fibroids
Disease control OngoingThis study tests whether a low-caffeine green tea extract (EGCG) can shrink uterine fibroids and improve pregnancy and live birth rates in women aged 18-40 who have been trying to conceive for at least six months. Participants take the extract and are monitored for changes in fib…
Phase 3 • Sponsor: Yale University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Drug Combo's Long-Term safety under scrutiny in blood disease patients
Disease control OngoingThis study follows patients who have already been taking ruxolitinib alone or with panobinostat in earlier trials and are still benefiting. Researchers will track side effects over time to see how safe these drugs are for long-term use. About 296 participants with conditions like…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug combo aims to stop blood cancer relapse after transplant in kids
Disease control OngoingThis study tests whether giving two drugs, decitabine and filgrastim, after a stem cell transplant can help prevent blood cancers like AML and MDS from coming back in children and young adults. About 37 participants will receive the drug combination for up to 6 cycles. The main g…
Phase 2 • Sponsor: Franziska Wachter • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New injection could help kids with lupus avoid flares
Disease control OngoingThis study tests a weekly injection of belimumab, a drug that blocks a protein involved in lupus inflammation, in 25 children aged 5 to 17 with active lupus. The goal is to see if the drug reaches similar levels in the blood as in adults and to check its safety. If it works, it c…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a B-Cell blocker tame lupus?
Disease control OngoingThis phase 2 trial is testing whether an experimental drug called obexelimab can safely reduce disease activity in people with systemic lupus erythematosus (SLE). The study enrolls about 190 adults aged 18 to 70 with active lupus. Participants are randomly assigned to receive eit…
Phase 2 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a new drug combo push CML into deep remission?
Disease control OngoingThis phase 2 trial is testing whether adding the experimental drug asciminib to standard treatments (imatinib, nilotinib, or dasatinib) can achieve deeper molecular responses in adults newly diagnosed with chronic-phase chronic myeloid leukemia (CML). Participants receive one of …
Phase 2 • Sponsor: University of Jena • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New combo therapy targets high-risk MDS in early trial
Disease control CancelledThis study tests a new two-drug combination (pacritinib plus azacitidine) for people with moderate to very high risk myelodysplastic syndrome (MDS), a bone marrow disorder. The first part finds the safest dose of pacritinib, and the second part checks how well the combination wor…
Phase 1/2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New knee implant under review: could it ease arthritis pain?
Disease control OngoingThis study is testing the Persona Ti-Nidium knee implant in 240 people who need total knee replacement due to conditions like osteoarthritis or rheumatoid arthritis. The goal is to see if the implant is safe and improves knee function and pain. Participants will be followed over …
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a targeted drug outperform standard care for rare blood cancers?
Disease control OngoingThis trial compares the drug ruxolitinib against the best available standard treatments for people with high-risk polycythemia vera (PV) or essential thrombocythemia (ET), two rare blood cancers that cause overproduction of blood cells and can lead to clots, bleeding, and severe …
Phase 2 • Sponsor: RWTH Aachen University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Ceramic hip resurfacing: a Metal-Free future for joint replacement?
Disease control OngoingThis study is testing a new type of hip resurfacing device made entirely of ceramic, designed for people with hip osteoarthritis, necrosis, or dysplasia. The goal is to see if it is as safe and effective as existing metal-on-metal devices, but without releasing metal ions into th…
Sponsor: Embody Orthopaedic Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a modified interferon rein in early myelofibrosis?
Disease control OngoingThis phase 3 trial is testing whether ropeginterferon alfa-2b, a biologic drug, can help control blood cell counts and symptoms in adults with early or low-risk primary myelofibrosis, a bone marrow disorder. Participants receive either the drug or a placebo every two weeks for up…
Phase 3 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug sonelokimab aims to ease psoriatic arthritis pain
Disease control OngoingThis study tests a drug called sonelokimab in 960 adults with active psoriatic arthritis who have not used biologic treatments before. The goal is to see if it reduces joint pain and swelling better than a placebo. Participants receive injections over several months, and research…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat cancers
Disease control OngoingThis study tests a new treatment using a patient's own immune cells that are genetically modified to better recognize and attack certain solid tumors. It is for people with advanced cancers like synovial sarcoma that have not responded to other treatments. The goal is to see if t…
Phase 2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for babies with rare calcification disease: first drug trial launches
Disease control OngoingThis study tests a new drug called INZ-701 in up to 16 infants (up to 1 year old) with rare genetic conditions (ENPP1 or ABCC6 deficiency) that cause dangerous calcium buildup in arteries and other problems. The main goal is to check the drug's safety and how the body handles it,…
Phase 1 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New lupus drug candidate enters Mid-Stage trial
Disease control OngoingThis Phase 2 trial tests whether the experimental drug SAR441344 can safely control disease activity in people with active systemic lupus erythematosus (SLE). About 109 adults aged 18–70 will receive either the drug or a placebo for 24 weeks. The main goal is to see if more peopl…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for older leukemia patients: targeted combo shows promise
Disease control OngoingThis study is for adults with a specific type of acute myeloid leukemia (CD123+ AML) who cannot receive standard strong chemotherapy. It tests a new drug, tagraxofusp, added to two other drugs (venetoclax and azacitidine) to see if it helps more people achieve complete remission.…
Phase 2 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for lupus skin sufferers: Long-Term drug trial launches
Disease control By invitation onlyThis study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new pill ease arthritis in kids?
Disease control OngoingThis study is testing an oral medication called upadacitinib in children with polyarticular juvenile idiopathic arthritis (JIA), a condition causing joint inflammation. The goal is to understand how the drug moves through the body, its safety, and how well children tolerate it. P…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Engineered immune cells take on lupus in first human test
Disease control OngoingThis early-phase trial is testing a one-time treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't improved with standard treatments. Obe-cel is made by taking a patient's own immune cells, engineering them to target and attack faulty B cells…
Phase 1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could this IV drug tame lupus kidney flares?
Disease control OngoingThis phase 3 study tests anifrolumab, an IV drug, against placebo in 359 adults with active lupus nephritis (kidney inflammation from lupus). The main goal is to see if more patients achieve complete kidney response, meaning better kidney function and less protein in urine. The t…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new drug reduce bloodletting for polycythemia vera?
Disease control CancelledThis trial investigates whether ropeginterferon alfa-2b can help people with polycythemia vera, a condition where the body makes too many red blood cells. The study will compare the drug to standard care, which includes phlebotomy (removing blood) and aspirin. About 70 adults wit…
Phase 4 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug aims to tame rare immune storms
Disease control OngoingThis phase 2 study tests a drug called MAS825 in 17 people with rare genetic conditions that cause severe inflammation. The goal is to see if the drug can prevent disease flares better than a placebo. Participants will be monitored for safety and effectiveness over several period…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New shot may tame stubborn lupus skin lesions
Disease control OngoingThis study tests anifrolumab, a biologic drug given as a shot, for adults with chronic or subacute lupus skin rashes that didn't get better with antimalarial drugs. About 306 participants will receive either anifrolumab or a placebo to see if the drug can reduce skin disease acti…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug could shrink rare joint tumors without surgery
Disease control OngoingThis study tests an investigational drug called emactuzumab for people with a rare joint tumor (TGCT) that can't be removed surgically. About 128 participants will receive either the drug or a placebo to see if it shrinks tumors and improves joint function. The goal is to offer a…
Phase 3 • Sponsor: SynOx Therapeutics Limited • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Radioactive therapy targets stubborn leukemia in early trial
Disease control OngoingThis study tests a new radioactive drug called [177Lu]Lu-PentixaTher in people with acute leukemia that has come back or not responded to standard treatments. The drug seeks out and delivers radiation directly to leukemia cells that have a specific marker (CXCR4). The main goals …
Phase 1/2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Blood cancer drug ASTX727 gets extended trial for ongoing patients
Disease control By invitation onlyThis study offers continued treatment with the drug ASTX727 to adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in earlier studies. The main goal is to monitor long-term safety. About 332 partici…
Phase 2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New lupus shot shows promise in major trial
Disease control OngoingThis study tests a new medicine called anifrolumab, given as a shot under the skin, for adults with moderate-to-severe lupus. The goal is to see if it can better control disease activity compared to a placebo, when added to standard treatments. About 367 participants are involved…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New CML drug combo strategy aims for deeper remission without lifelong side effects
Disease control OngoingThis study tests a new drug, asciminib, as the first treatment for adults newly diagnosed with chronic myeloid leukemia (CML). If the drug alone does not achieve a deep response within 2 to 3 years, a low dose of another targeted therapy is added. The goal is to see if this appro…
Phase 2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a biologic drug outperform standard therapy for a rare blood cancer?
Disease control OngoingThis phase 3 trial compares the biologic drug P1101 (ropeginterferon alfa-2b) against the standard drug anagrelide in people with essential thrombocythemia, a rare blood cancer that causes too many platelets. The study enrolls adults who have not responded well to the first-line …
Phase 3 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control By invitation onlyThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for rare leukemia: targeted pill shows promise in early trial
Disease control OngoingThis study tests a drug called cobimetinib in people with a rare blood cancer (CMML) that has certain gene mutations. The goal is to see if the drug can shrink or control the cancer. Fourteen adults with either new or treatment-resistant CMML will take the drug daily in 3-week-on…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New lupus pill shows promise in Mid-Stage trial
Disease control OngoingThis Phase 2 study tests an experimental oral drug called ESK-001 in 408 adults with active systemic lupus erythematosus (SLE). Participants receive either ESK-001 or a placebo for 48 weeks to see if the drug can reduce disease activity. The goal is to find a new treatment option…
Phase 2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New lupus drug enpatoran tested for long-term safety
Disease control OngoingThis study looks at the long-term safety and effectiveness of enpatoran, an experimental drug for lupus. About 379 people who completed a previous 24-week study will take different doses of enpatoran or a placebo for up to 194 weeks. The goal is to see if the drug is safe and hel…
Phase 2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can pressurized oxygen boost cord blood transplants?
Disease control OngoingThis study tests whether giving patients hyperbaric oxygen (breathing pure oxygen in a pressurized chamber) after an umbilical cord blood stem cell transplant helps the donated stem cells grow faster. The trial enrolls people with blood cancers like leukemia or lymphoma who lack …
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo pill shows promise for rare bone marrow cancer
Disease control OngoingThis Phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a rare bone marrow disorder. About 430 adults who have not had prior JAK inhibitor treatment will take either the combination or …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug RAY121 tested for Long-Term control of autoimmune diseases
Disease control By invitation onlyThis study is a long-term extension of an earlier trial, testing the safety of a drug called RAY121 in people with six different immune system disorders, including antiphospholipid syndrome and immune thrombocytopenia. Participants have already completed four doses of RAY121 and …
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a simple drug during brain surgery prevent Life-Threatening sodium swings?
Disease control By invitation onlyThis trial tests whether giving a low-dose infusion of desmopressin (dDAVP) during surgery for complex brain tumors around the pituitary gland can prevent dangerously high sodium levels (hypernatremia) in the first 24 hours after surgery. High sodium can cause brain bleeding, sei…
Phase 4 • Sponsor: Zhaoyun Zhang • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Psoriasis drug bimekizumab: new study looks at gene changes
Disease control OngoingThis study tests the drug bimekizumab in 89 adults with moderate to severe plaque psoriasis, some of whom also have psoriatic arthritis. Researchers will measure changes in gene activity in skin samples after 48 weeks of treatment. The goal is to understand how the drug affects t…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a drug free myelofibrosis patients from frequent blood transfusions?
Disease control OngoingThis phase 3 study tests whether the drug luspatercept can help people with myelofibrosis-related anemia become independent of red blood cell transfusions. Participants are adults with myelofibrosis who are already taking a JAK inhibitor and need regular transfusions. The study c…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New antibody drug shows promise for rare bone cancer
Disease control OngoingThis phase 2 trial tests a drug called INBRX-109 in people with a rare bone cancer (conventional chondrosarcoma) that cannot be removed by surgery or has spread. The drug is a lab-made antibody designed to kill cancer cells. About 206 participants will receive either INBRX-109 or…
Phase 2 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can a 4-Minute chat rival a Dietitian's hour for heart health?
Disease control OngoingThis study tests whether a short, standardized 4-minute heart-healthy talk is as effective as a full 60-minute personalized session with a dietitian for lowering LDL cholesterol and improving diet. Participants are adults aged 30–80 with rheumatoid arthritis, psoriatic arthritis,…
Sponsor: Diakonhjemmet Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Patients choose: transplant or Non-Transplant for rare bone marrow cancer?
Disease control OngoingThis study looks at two treatment options for people with a high-risk form of myelofibrosis, a rare bone marrow cancer. Participants choose whether they want a stem cell transplant or the best non-transplant treatments available. Researchers then track survival and quality of lif…
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Withdrawn study sought to boost RA remission with education and team care
Disease control CancelledThis study was designed to test whether a combination of an educational booklet, team-based care from a rheumatologist, physical therapist, and psychologist, plus nurse-led phone calls and home symptom tracking, could help more Hispanic adults with rheumatoid arthritis achieve re…
Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for AML patients? quizartinib trial targets Tough-to-Treat leukemia
Disease control OngoingThis Phase 3 trial is testing whether adding the drug quizartinib to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) that lacks a specific genetic mutation (FLT3-ITD). About 700 participants will receive either quizartinib or a placebo alongsi…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered t cells with a kill switch aim to make stem cell transplants safer
Disease control OngoingThis study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Smart dosing strategy could keep rheumatoid arthritis under control
Disease control OngoingThis study compares two ways of managing rheumatoid arthritis in people taking adalimumab. One group gets standard care, while the other has their dose adjusted based on regular blood tests that measure drug levels and antibodies. The goal is to see if personalized dosing helps m…
Phase 4 • Sponsor: Diakonhjemmet Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a diabetes drug shield kidneys from lupus damage?
Disease control OngoingThis phase 2 trial tests whether dapagliflozin, a drug already used for diabetes and chronic kidney disease, can slow kidney damage in people with lupus nephritis. Lupus nephritis is a serious complication of lupus that causes kidney inflammation and can lead to chronic kidney di…
Phase 1/2 • Sponsor: Hospital Civil Juan I. Menchaca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Suicide Gene-Equipped t cells aim to make stem cell transplants safer
Disease control OngoingThis trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo aims to control rare leukemia without harsh chemo
Disease control OngoingThis Phase 3 trial tests whether adding ivosidenib (a targeted pill) to standard azacitidine helps adults with a specific IDH1-mutated acute myeloid leukemia (AML) who cannot have intensive chemotherapy. About 146 participants receive either the combo or a placebo plus azacitidin…
Phase 3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Childhood leukaemia trial seeks best chemo cocktail
Disease control OngoingThis trial investigates the best way to treat children with acute myeloid leukaemia (AML) by comparing different chemotherapy drugs and doses. It tests whether adding up to three doses of the targeted drug gemtuzumab ozogamicin to standard chemo is safe and effective. The study a…
Phase 3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug shows promise for rare joint tumor
Disease control OngoingThis phase 3 trial tests the drug pexidartinib in 40 adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that causes pain and limits movement. The study focuses on people whose tumors are severe and cannot be helped by surgery. Researchers are…
Phase 3 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase 2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo aims to boost survival in older AML patients
Disease control OngoingThis phase 3 trial compares a two-drug combination (pevonedistat plus azacitidine) against azacitidine alone in 302 older or unfit adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The main goal is to see if the combination …
Phase 3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to fight Hard-to-Treat sarcomas
Disease control OngoingThis phase II trial tests two immunotherapy drugs, oleclumab and durvalumab, in 75 people with advanced sarcoma (angiosarcoma, dedifferentiated liposarcoma, or osteosarcoma) that has returned, spread, or stopped responding to treatment. The goal is to see if the combination can s…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Promising combo offers hope for older AML patients
Disease control OngoingThis phase 3 study tested whether adding venetoclax to azacitidine helps people with untreated acute myeloid leukemia (AML) who cannot receive standard chemotherapy. About 443 adults took part, with two-thirds receiving the drug combo and one-third getting a placebo plus azacitid…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New antibody drug aims to halt Scleroderma's grip
Disease control OngoingThis Phase 3 trial tests whether the drug divozilimab can reduce skin thickening and protect lung function in people with systemic scleroderma, a rare autoimmune disease. About 152 adults and teens with active disease will receive either the drug or a placebo. The study is double…
Phase 3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for rare tumor patients: AL102 drug trial launches
Disease control OngoingThis study tests a drug called AL102 (varegacestat) in people with desmoid tumors that are growing. Desmoid tumors are non-cancerous but can be painful and invasive. The trial has two parts: Part A checks safety and tumor changes, and Part B compares AL102 to a placebo to see if …
Phase 2/3 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug SPY002-072 aims to tame multiple inflammatory joint diseases
Disease control OngoingThis Phase 2 study tests an experimental drug called SPY002-072 in 285 adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis. Participants receive either the drug or a placebo, and researchers measure changes in disease ac…
Phase 2 • Sponsor: Spyre Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Fibroid surgery Follow-Up drug trial pulled before it began
Disease control CancelledThis study aimed to see if taking Myfembree (a combination pill) daily after fibroid removal surgery could delay the return of fibroids and improve quality of life. It was designed for premenopausal women with uterine fibroids who had surgery. However, the trial was withdrawn bef…
Phase 4 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug aims to tame muscle inflammation in myositis
Disease control OngoingThis phase 2 trial tests whether nipocalimab, given intravenously, can improve symptoms of active idiopathic inflammatory myopathies (myositis) better than a placebo. About 36 adults with myositis will receive either nipocalimab or a placebo, along with standard steroid treatment…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New robot could transform hysterectomy surgery
Disease control OngoingThis study is testing a new robotic system, the Medtronic Hugo™, for performing hysterectomies. It includes 70 patients with conditions like uterine fibroids, endometriosis, or certain cancers. The goal is to see if the robot is safe and can complete the surgery without switching…
Sponsor: Medtronic - MITG • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for tough leukemia: drug combo targets hidden cancer cells
Disease control OngoingThis early-phase study tests a new drug called uproleselan combined with two standard chemotherapy drugs for children and teens with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. The drug works by blocking a protein that helps c…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Real-World study tests upadacitinib for back pain in axial spondyloarthritis
Disease control OngoingThis study looks at how well upadacitinib (RINVOQ) works for people with axial spondyloarthritis, a type of inflammatory arthritis that causes chronic back pain. About 338 adults in Germany will take the drug as prescribed by their doctor and be followed for 52 weeks. Researchers…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New RA pill takes on tofacitinib in Head-to-Head trial
Disease control OngoingThis phase 3 trial tests whether a new oral drug called TLL-018 works better than tofacitinib for active rheumatoid arthritis. The study includes 459 adults aged 18-65 who have not responded well to or cannot tolerate biologic treatments. Participants take either TLL-018 or tofac…
Phase 3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to tame Cushing's disease with fewer side effects
Disease control By invitation onlyThis study tests whether adding cabergoline to osilodrostat works better than osilodrostat alone for controlling Cushing's disease. About 50 adults with active Cushing's disease will receive either the combination or the single drug. The goal is to see if the combo can lower cort…
Phase 4 • Sponsor: University of Basrah • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New implant aims to strengthen shoulder tendon repair after replacement
Disease control OngoingThis study is testing a special implant (Tapestry) that helps repair a key shoulder tendon (subscapularis) during shoulder replacement surgery. About 100 adults with shoulder arthritis or injury will be followed for 2 years to see if the tendon heals better with the implant. The …
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can magnetic waves tame autoimmune disease? new trial begins
Disease control By invitation onlyThis study tests a non-invasive device that uses low-frequency electromagnetic fields to improve communication between immune cells. 120 adults with lupus, rheumatoid arthritis, or multiple sclerosis will receive either active or sham sessions three times a week for 12 weeks. The…
Phase 1/2 • Sponsor: Truway Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug aims to slow lung damage in rare autoimmune disease
Disease control OngoingThis phase 2 trial tests whether tulisokibart can safely slow lung scarring in people with systemic sclerosis and interstitial lung disease. About 154 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces the yearly decline in lung fu…
Phase 2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Lupus drug trial hopes to tame flares with targeted antibody
Disease control OngoingThis Phase 3 study tests whether obinutuzumab, an antibody drug given by IV, can better control active lupus compared to a placebo. About 303 adults with lupus who have high disease activity and specific antibodies are taking part. All participants continue their usual lupus medi…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Blood cancer drug venetoclax gets Long-Term safety check
Disease control OngoingThis study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Electric pulses plus chemo aimed at rare tumor, but study pulled
Disease control CancelledThis study planned to test electrochemotherapy (ECT) with bleomycin in people with desmoid fibromatosis, a non-cancerous but locally aggressive tumor. The goal was to see if the treatment could shrink the tumor and improve symptoms like pain. However, the study was withdrawn befo…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy for AML enters early human testing
Disease control OngoingThis early-phase study tests a new drug called cusatuzumab alongside usual treatments for adults with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The main goal is to check the safety and side effects of the combination. About 61 participants will receive …
Phase 1 • Sponsor: OncoVerity, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for hard-to-treat blood cancers: experimental drug imetelstat tested in phase 2 trial
Disease control OngoingThis study tests an experimental drug called imetelstat in 46 adults with high-risk myelodysplastic syndromes or acute myeloid leukemia that did not improve after standard therapy. The goal is to see if the drug can improve blood cell counts and control the disease. Participants …
Phase 2 • Sponsor: GCP-Service International West GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for older blood cancer patients: smarter transplants aim to cut relapse
Disease control OngoingThis clinical trial is testing different treatment strategies to improve outcomes for older adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are getting a stem cell transplant. The study compares a new pre-transplant drug (Vyxeos) with stan…
Phase 2/3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Leukemia drug holiday: study tests if patients can pause treatment
Disease control OngoingThis study looks at whether people with chronic myeloid leukemia (CML) who have had a stable, deep response to treatment for at least two years can safely stop taking their daily targeted therapy (TKI). It involves 17 adults who have been on TKI for over three years. The main goa…
Phase 2 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Shorter treatment course may ease side effects for AML patients
Disease control OngoingThis study tests a new way of giving two drugs—venetoclax and azacitidine—to adults with acute myeloid leukemia (AML) who are not healthy enough for standard chemotherapy. Instead of the usual 7 days of azacitidine, this approach uses only 5 days per cycle to try to reduce infect…
Phase 2 • Sponsor: University of Leipzig • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for myelofibrosis patients with dangerous low platelet counts
Disease control OngoingThis phase 3 study tests a drug called pacritinib against standard treatments chosen by the doctor in people with myelofibrosis who have very low platelet counts (below 50,000). The goal is to see if pacritinib can shrink the spleen and reduce symptoms like tiredness, pain, and i…
Phase 3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Which treatment works best for Dupuytren's? major trial aims to find out
Disease control OngoingThis study compares three treatments for Dupuytren's contracture, a hand condition that causes fingers to bend inward. The treatments are needle fasciotomy (a quick in-office procedure), collagenase injection (a drug that breaks up the tight cord), and surgery (limited fasciectom…
Phase 4 • Sponsor: Tampere University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a pill tame lupus? large trial tests upadacitinib
Disease control OngoingThis phase 3 study tests whether upadacitinib (RINVOQ), a drug already used for arthritis, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the drug or a placebo daily for a year. Researchers will measure how well it reduces disease acti…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Should sarcoidosis patients stay on infliximab? new trial aims to find out
Disease control OngoingThis phase 3 trial looks at whether people with severe sarcoidosis who are in remission should stop or continue taking infliximab. 32 adults who have been on infliximab for at least 6 months and are stable on low-dose steroids will be randomly assigned to stop or continue the dru…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a common supplement ease lupus?
Disease control OngoingThis study tests whether N-acetylcysteine (NAC), an antioxidant supplement, can help people with systemic lupus erythematosus (SLE). About 290 participants will first take NAC for 3 months to find a tolerable dose, then be randomly assigned to continue NAC or switch to a placebo …
Phase 2 • Sponsor: State University of New York - Upstate Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy targets tough blood cancers in early trial
Disease control OngoingThis study tests a new drug called bexmarilimab, given together with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The goal is to first find a safe dose and then see if the combination helps shrink or control the cancer. About 181 adults are taki…
Phase 1/2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New procedure aims to shrink kidney tumors without surgery
Disease control OngoingThis study tests a minimally invasive procedure that blocks blood flow to kidney angiomyolipomas (non-cancerous tumors). The goal is to shrink the tumors and stop bleeding while preserving kidney function. Researchers will follow 50 patients for one year to check safety and effec…
Sponsor: Botkin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New combo treatment aims to save hips from collapse
Disease control OngoingThis study tests a procedure for people with early-stage osteonecrosis (bone death) of the hip. Doctors drill into the hip bone, inject a concentrated sample of the patient's own bone marrow, and add a special bone graft material called Genex. The goal is to see if this helps bon…
Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug hopes to tame hardening skin disease
Disease control PausedThis study tests a new drug called CM-101 for people with systemic sclerosis, a disease that causes skin hardening and organ damage. About 45 adults will receive either the drug or a placebo to check safety and how well the body tolerates it. The goal is to see if CM-101 can redu…
Phase 2 • Sponsor: ChemomAb Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could a tiny neck implant calm rheumatoid arthritis without pills?
Disease control OngoingThis study tests a small device implanted on the vagus nerve in the neck to treat moderate to severe rheumatoid arthritis. About 243 adults who did not get enough relief from standard drugs will receive either active or inactive stimulation for 12 weeks, then all will receive act…
Phase 3 • Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo shows promise for Tough-to-Treat leukemia
Disease control By invitation onlyThis study tests a combination of three drugs (homoharringtonine, venetoclax, and azacitidine) in 40 adults newly diagnosed with a rare and aggressive leukemia called mixed-phenotype acute leukemia (MPAL). The goal is to see if this drug combo can safely help more patients achiev…
Phase 2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer
Disease control OngoingThis study tests whether adding the drug selinexor to the standard treatment ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 353 adults who have not yet been treated for their condition will take either the combin…
Phase 3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Which airway method saves more kids? major trial aims to find out
Disease control PausedThis study tests three ways emergency responders help children breathe: a bag-mask, a throat tube, or a breathing tube. It includes 3,000 children under 18 with cardiac arrest, severe injury, or breathing failure. The goal is to see which method leads to more days alive and out o…
Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo shows promise for rare bone marrow cancer
Disease control OngoingThis early-stage trial tests an experimental drug called INCB057643, given alone or with the standard drug ruxolitinib, in about 140 adults with myelofibrosis or other advanced blood cancers. The main goal is to check safety and side effects, while also measuring if the drug can …
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New shoulder replacement system tracked in global study
Disease control By invitation onlyThis study is following 110 people who received a Tornier HRS shoulder replacement to see how well it improves pain and function. Participants have conditions like arthritis, fractures, or rotator cuff tears. The goal is to collect long-term safety and performance data for regula…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New device aims to starve tumors by cutting off their blood supply
Disease control OngoingThis study tests a device called GPX that blocks blood flow to tumors or other targeted areas. About 114 adults with conditions like kidney tumors or bone tumors will receive the treatment. The goal is to see if the device is safe and works well at reaching and blocking small blo…
Sponsor: Fluidx Medical Technology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo therapy aims to halt prostate cancer spread
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug durvalumab to precise radiation (SBRT) can better control prostate cancer that has returned and spread to a few spots (oligometastases). About 96 men with hormone-sensitive prostate cancer will be randomly assigned t…
Phase 2 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells take on lupus in tiny trial
Disease control OngoingThis Phase 2 trial is testing a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE). Descartes-08 uses a patient's own immune cells, modified to target a protein called BCMA, to try to control the disease. Only 6 participants with active lupus des…
Phase 2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug aims to stop hip bone death from steroids
Disease control OngoingThis study tests a new drug called RAB001 in people with early-stage hip bone damage caused by long-term steroid use. About 160 participants will receive either a low, medium, or high dose of RAB001, or a standard bone drug (alendronate). The goal is to see if RAB001 can reduce t…
Phase 2 • Sponsor: ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New pill could shrink rare joint tumors without surgery
Disease control OngoingThis phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the dr…
Phase 3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Double-Drug attack on rheumatoid arthritis shows promise in new trial
Disease control OngoingThis Phase III trial tests whether combining baricitinib with an anti-TNF drug (adalimumab or etanercept) works better than baricitinib alone for people with rheumatoid arthritis who haven't responded to prior treatments. The study involves 160 adults aged 18-65 with active disea…
Phase 3 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for blood cancer patients: using mismatched donors for transplants
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Heart rhythm showdown: ablation may beat drugs for ventricular tachycardia
Disease control OngoingThis trial tests whether a procedure called catheter ablation works better than anti-arrhythmic drugs for people with structural heart disease who have had a dangerous fast heart rhythm (ventricular tachycardia). About 162 participants will be randomly assigned to either ablation…
Sponsor: Western Sydney Local Health District • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo aims to wipe out leukemia cells in High-Risk patients
Disease control OngoingThis phase 2 trial tests whether adding daratumumab, an antibody that targets a protein on leukemia cells, to standard chemotherapy can clear all signs of cancer in adults with very high-risk T-cell acute lymphoblastic leukemia (T-ALL). About 31 patients aged 18-65 will receive t…
Phase 2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for psoriatic arthritis: tildrakizumab shows promise in Long-Term trial
Disease control OngoingThis phase 3 study is testing the long-term safety and effectiveness of tildrakizumab, a biologic drug given as an injection, in people with psoriatic arthritis. Researchers are tracking side effects and how well the drug reduces joint pain, swelling, and other symptoms over time…
Phase 3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New stem cell mix aims to make transplants safer for blood cancer patients
Disease control OngoingThis phase 3 trial tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a special mix of stem cells and immune cells from a matched donor, designed to reduce a serious side effect called graft-versus-host disease. The study compares …
Phase 3 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail shows promise for rare leukemia
Disease control OngoingThis study tests a combination of two drugs, azacitidine and venetoclax, in people with a high-risk form of chronic myelomonocytic leukemia (CMML). The goal is to see if the combo can shrink or control the cancer better than current treatments. About 44 adults will take part, and…
Phase 2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
CAR-T cells take on rheumatoid arthritis in Head-to-Head trial
Disease control OngoingThis phase I/II trial compares a single dose of CAR-T cell therapy (KYV101) to two doses of rituximab in 13 people with active, treatment-resistant rheumatoid arthritis. The main goals are to check safety and see if the CAR-T treatment can turn off certain immune markers linked t…
Phase 1/2 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Vitamin e in knee implants: a Long-Term showdown
Disease control OngoingThis study looks at two kinds of plastic used in total knee replacement surgery: one with vitamin E and one without. The goal is to see which one lasts longer, causes less wear, and helps patients move better. About 605 adults with knee arthritis or similar problems took part, an…
Sponsor: Aesculap AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for myositis: early IVIg may boost recovery
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past y…
Phase 2/3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Hip replacement stem under review: 5-Year safety and performance study
Disease control OngoingThis study looks at the safety and performance of a cemented hip stem (TrendHip®) in 119 people who had hip replacement surgery. It tracks pain, function, and quality of life for up to 5 years after surgery. The goal is to confirm the device works well in everyday use.
Sponsor: Aesculap AG • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for PAH patients: Long-Term drug safety trial opens
Disease control By invitation onlyThis study looks at the long-term safety of the drug ralinepag in people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. About 1,000 adults who were in earlier ralinepag studies can join. The goal is to see if the drug remains s…
Phase 3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Phase 1 • Sponsor: David Porter • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis phase 3 study tests litifilimab, an experimental drug, in 548 adults with active systemic lupus erythematosus (SLE) who are already on standard treatments. Participants receive either high or low doses of litifilimab or a placebo as injections every 4 weeks for 52 weeks. The…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New knee implant under review: will it hold up?
Disease control OngoingThis study follows 100 people who received a new type of knee replacement device called EVOLUTION® NitrX™. The goal is to see how safe and effective it is over time. Participants have conditions like arthritis or knee damage. The main measure is a patient-reported score of knee f…
Sponsor: MicroPort Orthopedics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Can a single drug free PMR patients from steroids?
Disease control OngoingThis phase 3 trial tests whether rituximab, a drug that calms certain immune cells, can help people with polymyalgia rheumatica (PMR) stop taking steroids without their symptoms returning. The study includes 174 adults who are currently experiencing a PMR relapse and cannot lower…
Phase 3 • Sponsor: Sint Maartenskliniek • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Email your doctor to beat gout: new trial tests remote care
Disease control OngoingThis study tests whether regular email communication between gout patients and their doctors can help lower uric acid levels more effectively than standard care. 204 adults with confirmed gout will either follow usual care or use a secure messaging system to adjust their medicati…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for rare blau syndrome: tofacitinib under the microscope
Disease control By invitation onlyThis study is looking at how well the drug tofacitinib works for people with Blau syndrome, a rare genetic condition that causes inflammation in the joints, eyes, and skin. Researchers will review medical records from 24 participants to see if tofacitinib helps control the diseas…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Remote Follow-Up for pituitary tumors: safe or risky?
Disease control By invitation onlyThis study compares the safety of routine telephone or video follow-ups versus in-person visits for patients with non-functioning pituitary tumors. Over two years, 812 participants will be randomly assigned to remote or in-person check-ups. The goal is to see if remote follow-up …
Sponsor: Zealand University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Knee implant study tracks 10-Year performance
Disease control OngoingThis study looks at how well a specific knee replacement implant works over 10 years. Researchers are checking the safety and performance of the Legion knee implant in 126 people who already received it. The goal is to see how long the implant lasts and if it helps patients with …
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis study tests a new drug called litifilimab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 562 adults already on standard lupus treatments will receive either litifilimab or a placebo as a shot every 4 weeks for 52 weeks. The goa…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New study tracks leukemia Drug's Real-Life impact
Disease control OngoingThis study follows about 100 adults with acute myeloid leukemia (AML) who are already prescribed venetoclax by their doctors in Israel. Researchers will track how long patients live and how many achieve remission during routine care. The goal is to understand the drug's real-worl…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New injection shows promise for straightening penile curvature
Disease control OngoingThis study tested whether adding Fibrorestil® injections to standard care (traction therapy and pills) can better reduce penile curvature in men with Peyronie's disease. 38 men with stable curvature between 30 and 90 degrees participated. The main goal was to measure curvature ch…
Sponsor: Lyx Institute • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental Cell-Drug combo takes on tough leukemia
Disease control OngoingThis early-phase trial is testing whether a new immune cell therapy called CART123, given together with the drug ruxolitinib, is safe for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The study will enroll 12 adults who have no other c…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Gene-Edited super cells take on childhood leukemia
Disease control OngoingThis early-stage trial tests a new treatment for children aged 6 months to 16 years whose acute myeloid leukemia has returned. The therapy uses donor immune cells that have been gene-edited with a technique called base editing to better target and kill leukemia cells. The main go…
Phase 1 • Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Compassionate use study offers AML patients continued access to experimental oral chemo
Disease control OngoingThis study gives a small group of adults with acute myeloid leukemia (AML) continued access to an oral form of the chemotherapy drug azacitidine after they finished a previous trial. The main goal is to track any side effects and see how safe the drug is over a longer period. Abo…
Sponsor: Hikma Pharmaceuticals LLC • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for rare blood cancer: drug duo targets enlarged spleen
Disease control OngoingThis study tests whether adding the experimental drug navitoclax to the standard drug ruxolitinib can shrink the spleen and reduce symptoms better than other available treatments in adults with myelofibrosis that has returned or not improved. About 330 participants will be random…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Engineered immune cells take on lupus and scleroderma in first human test
Disease control OngoingThis early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy f…
Phase 1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Pharmacists take on heart disease: new study tests community-based risk reduction
Disease control OngoingThis study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle change…
Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug combo targets tough leukemia in early trial
Disease control OngoingThis study tests a new combination of two drugs (gemtuzumab ozogamicin and gilteritinib) for adults with a specific genetic form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial aims to see if the combination is safe and helps control th…
Phase 2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New RNA drug aims to reduce blood removal in polycythemia vera patients
Disease control OngoingThis study tests a new drug called SLN124 in 69 adults with polycythemia vera, a condition where the body makes too many red blood cells. The drug works by blocking a protein that controls iron use, which may lower red blood cell production and reduce the need for regular blood r…
Phase 1/2 • Sponsor: Silence Therapeutics plc • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…
Phase 1/2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis study tests whether the drug deucravacitinib can safely control symptoms in people with active moderate-to-severe lupus. About 513 participants will receive either the drug or a placebo. The goal is to see if the drug reduces lupus disease activity better than placebo.
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill could tame lupus flares
Disease control OngoingThis Phase 3 trial tests whether the oral drug deucravacitinib can safely control moderate to severe lupus better than a placebo. About 516 adults with active lupus are taking either the drug or a dummy pill for several months. The goal is to see if the drug reduces lupus symptom…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Targeted radiation may extend life for patients with limited bone metastases
Disease control OngoingThis study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…
Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Canadian study monitors Venetoclax's Real-World impact on AML
Disease control OngoingThis study looks at how well the drug venetoclax works for adults with acute myeloid leukemia (AML) who cannot handle strong chemotherapy. About 210 people across Canada will take venetoclax pills daily as part of their normal care. Researchers will track their overall survival a…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental CAR-T therapy targets tough leukemia
Disease control PausedThis early-stage trial is testing a new treatment called CT0991, which uses specially engineered immune cells (CAR-T cells) to fight acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The study involves 24 adults aged 18-75 and aims to check saf…
Phase 1 • Sponsor: He Huang • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug combo may let CML patients pause treatment
Disease control OngoingThis phase 2 trial tests whether starting with a stronger drug (ponatinib) for 6 months, then switching to a standard drug (imatinib) for at least 30 months, can help adults with newly diagnosed chronic myeloid leukemia reach deep remission. The goal is to see if patients can the…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New chemo combo aims to boost leukemia survival after transplant
Disease control OngoingThis phase 2 trial tests a combination of two chemotherapy drugs, fludarabine and treosulfan, given before a stem cell transplant in adults aged 40-65 with acute myeloid leukemia (AML) in remission. The goal is to see if this conditioning regimen improves the chance of being aliv…
Phase 2 • Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New stem cell method aims to cut transplant risks for blood cancer patients
Disease control OngoingThis study tests a stem cell transplant method that removes certain immune cells (T and B cells) from donated stem cells before giving them to patients with blood cancers like leukemia or lymphoma. The goal is to help the new cells grow (engraft) while reducing the risk of graft-…
Phase 2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New transplant method aims to cut dangerous immune reaction in half-matched donors
Disease control OngoingThis study tests a stem cell transplant method that removes certain immune cells from the donor's blood to lower the chance of graft-versus-host disease (GvHD), a serious complication. It involves 3 patients with blood cancers or non-cancerous blood disorders who lack a perfectly…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for leukemia patients: asciminib trial underway
Disease control OngoingThis phase 2 trial tests asciminib, a daily oral drug, in 34 adults with chronic myeloid leukemia. Some participants have already tried one other treatment, while others are newly diagnosed. The study aims to see if asciminib can reduce cancer cells to very low levels. Doses may …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could a common steroid make AML treatment easier to tolerate?
Disease control By invitation onlyThis early-phase study tests whether adding the steroid dexamethasone to standard low-intensity chemotherapy is safe and tolerable for adults newly diagnosed with acute myeloid leukemia (AML) who cannot have intensive chemo. About 20 participants will receive the combination over…
Phase 1 • Sponsor: University of Vermont • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for AML patients: experimental vaccine-like therapy aims to prevent relapse
Disease control OngoingThis study tests an experimental drug called galinpepimut-S (GPS) in adults with acute myeloid leukemia (AML) who are in remission after second-line treatment. The goal is to see if GPS can help keep the cancer from coming back longer than the best available standard treatments. …
Phase 3 • Sponsor: Sellas Life Sciences Group • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug hopes to tame rare muscle and skin disease
Disease control OngoingThis study tests a drug called empasiprubart in adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Three participants receive either the drug or a placebo for 25 weeks, then are followed for 65 more weeks. The goal is to see if the drug is safe and…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Lupus drug sirolimus shows promise in phase 3 trial
Disease control OngoingThis phase 3 trial tests whether adding sirolimus (rapamycin) to standard treatment helps control active lupus better than placebo. 146 adults with active lupus despite standard care will receive either sirolimus or placebo for 24 weeks, with an option to continue for another 24 …
Phase 3 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a second stop be successful? nilotinib trial for CML relapse
Disease control OngoingThis study looks at whether taking nilotinib for two years can help people with chronic myeloid leukemia (CML) stay in remission after stopping their medication a second or third time. About 75 adults who previously tried and failed to stop treatment will take nilotinib and then …
Phase 2 • Sponsor: European LeukemiaNet • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Gene-Edited cell therapy for lupus trial pulled before it started
Disease control CancelledThis early-stage study aimed to test a single infusion of CB-010, a CRISPR-edited CAR-T cell therapy made from donor cells, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are availa…
Phase 1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:51 UTC
-
1304 RA patients tracked on filgotinib: will it hold up in real life?
Disease control OngoingThis study follows over 1300 adults with moderate to severe rheumatoid arthritis who are starting filgotinib (Jyseleca) as part of their normal care. Researchers will track how long patients stay on the drug, their pain, fatigue, and daily function over two years. The goal is to …
Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 26, 2026 17:02 UTC
-
RA treatment showdown: low activity vs. remission
Disease control OngoingThis study compares two treatment strategies for rheumatoid arthritis (RA): aiming for low disease activity versus aiming for remission. 340 adults with RA who are starting or already on disease-modifying drugs will be randomly assigned to one of these targets. The goal is to see…
Sponsor: Sint Maartenskliniek • Aim: Disease control
Last updated Jun 26, 2026 15:30 UTC
-
Can AI fake a cell image well enough to fool a lab expert?
Diagnosis OngoingResearchers want to know whether computer-generated images of ANA Hep-2 cells look real enough to pass as genuine microscope pictures. They ask 300 experienced lab professionals from multiple medical centers to judge a mix of real and AI-made images and to identify the cell patte…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
New scan could replace invasive test for Cushing's disease diagnosis
Diagnosis By invitation onlyThis study compares a new, non-invasive PET-MRI scan to the standard invasive test (IPSS) for finding pituitary tumors in people with Cushing's disease. About 43 adults with confirmed Cushing's will get both tests to see which is more accurate. The goal is to make diagnosis safer…
Sponsor: University Hospital, Basel, Switzerland • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
Could a simple light scan replace the skin pinch test for scleroderma?
Diagnosis OngoingThis study is testing a new, non-invasive imaging technique called spatial frequency domain imaging (SFDI) to measure skin thickness in people with scleroderma, an autoimmune disease that causes skin hardening. Currently, doctors assess skin fibrosis by pinching the skin, which i…
Sponsor: Boston University • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Saliva test could replace complex procedures for Cushing's diagnosis
Diagnosis OngoingThis study aims to see if a simple, inexpensive saliva test can accurately diagnose Cushing's syndrome, a condition where the body makes too much cortisol. Researchers will compare two automated saliva test methods in 380 adults who are already being checked for the condition. Th…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
New Ultrasound-Guided biopsy could prevent dangerous surgery for uterine tumors
Diagnosis OngoingThis study looks at whether a special biopsy done with ultrasound guidance before surgery can correctly tell if a uterine tumor is cancerous or not. It involves 19 women aged 35 and older who have suspicious uterine tumors. The goal is to avoid risky surgical procedures if the tu…
Sponsor: Institut Bergonié • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
Can a simple rinse stop the most painful complication of wisdom tooth surgery?
Prevention OngoingRemoving an impacted lower wisdom tooth can leave a painful complication called dry socket, where the protective blood clot in the empty socket breaks down. This trial compares two liquids used to rinse the socket right after extraction: normal saline and chlorhexidine, an antise…
Sponsor: CMH Lahore Medical College and Institute of Dentistry • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
New program aims to cut heart risks in psoriasis patients
Prevention OngoingThis study tests whether a dedicated care coordinator can help people with psoriasis or psoriatic arthritis reduce their risk of heart disease. About 520 adults aged 40-75 who do not already take cholesterol medication will receive support to manage risk factors like high cholest…
Sponsor: University of Pennsylvania • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingThis study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Eye surgery trial to prevent blindness in stickler syndrome pulled before start
Prevention CancelledThis study aimed to see if a surgical procedure called scleral buckling could prevent retinal detachment in people with Stickler syndrome, a genetic condition that raises the risk of vision loss. The plan was to treat one eye in patients aged 5 to 35 who had already lost vision i…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
3D printed inserts take on plantar fasciitis in new study
Symptom relief OngoingThis study tests whether 3D printed custom foot orthotics work as well as traditionally made ones for people with plantar fasciitis. About 30 adults with the condition will wear one type of insert for 8 weeks and report on comfort, fit, and pain relief. The goal is to see if the …
Sponsor: Prisma Health-Midlands • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can a Job-Focused rehab program keep arthritis patients employed?
Symptom relief OngoingPeople with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis often struggle to stay in work. This trial tests a 6-month vocational rehabilitation program called WORK-ON, which includes a coordinating occupational therapist, group sessions with peers, and ind…
Sponsor: The Danish Center for Expertise in Rheumatology • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New app aims to bridge depression care gap for MS patients
Symptom relief OngoingThis study tests a smartphone app called MS CATCH that lets people with multiple sclerosis regularly report their mood to their neurologist. The goal is to improve how doctors screen and treat depression in MS. About 100 adults with MS and mild-to-moderate depression are taking p…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Green tea compounds could soothe radiation burns in cancer care
Symptom relief By invitation onlyThis Phase 3 trial tests whether catechins (compounds found in green tea) given as a pill or spray can prevent or treat skin damage caused by radiation therapy. About 162 cancer patients will receive either catechins or a placebo, alongside standard care. The goal is to see if th…
Phase 3 • Sponsor: CARLOS FRANCISCO SAAVEDRA GARCIA • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can an Off-the-Shelf insole tame stubborn heel pain?
Symptom relief OngoingResearchers are studying whether a pre-made plantar insole, designed by shoe size and gender, helps adults with plantar fasciitis that has lasted at least six months and resisted other treatments. About 25 people will wear the insole during everyday walking for one year. The team…
Sponsor: Ente Ospedaliero Cantonale, Bellinzona • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
A personal nurse and a plan: could this ease the daily burden of arthritis?
Symptom relief OngoingThis trial tests a six-month program where a coordinating rheumatology nurse helps people with inflammatory arthritis set goals and plan actions to manage their condition. Participants also get access to physiotherapy, occupational therapy, and social work support as needed. The …
Sponsor: The Danish Center for Expertise in Rheumatology • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a Nine-Week group program help blood cancer patients grow through trauma?
Symptom relief OngoingResearchers in Greece are testing a nine-session group program called TRANSFORM for people who have finished treatment for blood cancers such as leukemia, lymphoma, and myeloma. The program combines teaching, reflection, coping exercises, and mindfulness to see whether it can spa…
Sponsor: University of West Attica • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Smart radiation targets cancer pain in bones
Symptom relief PausedThis early study tests a new type of radiation called biology-guided radiation therapy (BgRT) for people with cancer that has spread to the bones and causes pain. BgRT uses live PET scan signals to precisely aim radiation at active tumors during treatment. The goal is to see if a…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can a smarter oxygen device help lung disease patients move more?
Symptom relief By invitation onlyThis study tests whether using a portable oxygen concentrator (a lightweight, battery-powered device) during walking or exercise helps people with interstitial lung disease (ILD) or COPD feel less breathless and be more active in their daily lives. Twenty-four participants will t…
Sponsor: State University of New York at Buffalo • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Which exercise heals the knee tendon best? a Head-to-Head trial
Symptom relief By invitation onlyThis study compares two 12-week exercise programs—eccentric training and heavy-slow resistance training—in 30 adults aged 18–50 with patellar tendinopathy (knee pain lasting over 3 months). Researchers measure changes in tendon thickness, stiffness, strength, and pain to see whic…
Sponsor: University of Graz • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Sound waves vs. teen knee pain: a new test
Symptom relief OngoingThis trial tests whether shockwave therapy can improve knee function, balance, and fear of movement in adolescents with patellar tendinopathy, a common overuse injury causing knee pain. Fifty teens with pain in one knee will receive low-energy shockwaves to the tendon and thigh m…
Sponsor: Ahmed Alshimy • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Knee injection during surgery may ease arthritis pain
Symptom relief OngoingThis study tests whether an extended-release steroid injection (Zilretta) given during knee meniscus surgery can reduce pain and inflammation in people with osteoarthritis. 150 adults aged 40 and older are enrolled. Researchers will measure knee pain scores and inflammatory marke…
Phase 4 • Sponsor: The Cleveland Clinic • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Could a smart vaginal wand ease bladder pain without drugs?
Symptom relief CancelledThis study tests a new at-home device called the Floora Pelvic Rehabilitation Vaginal Dilator in 10 women with interstitial cystitis (painful bladder syndrome) and high-tone pelvic floor dysfunction. Participants use the device three times a week for 12 weeks, combining heat and …
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Could heat zap fibroids without surgery?
Symptom relief OngoingThis study looks at whether a procedure called microwave ablation can safely and effectively treat symptomatic uterine fibroids in 100 premenopausal women. The procedure uses ultrasound guidance to deliver heat directly to the fibroids, aiming to shrink them and reduce symptoms l…
Sponsor: Turku University Hospital • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
Could prehab training during chemo strengthen young cancer patients?
Symptom relief OngoingThis study tests whether a supervised strength and balance exercise program is feasible for children and teens undergoing chemotherapy for bone or soft tissue sarcoma in the lower leg. The goal is to see if this 'prehabilitation' can reduce muscle and bone weakening, and improve …
Sponsor: Technical University of Munich • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Healing from home: virtual reiki tested for lupus pain relief
Symptom relief OngoingThis pilot study will test whether virtual Reiki therapy can reduce pain and improve well-being in people with lupus. Twenty adults with lupus will receive 20-minute Reiki sessions once a week for 8 weeks, delivered remotely by a certified practitioner. Researchers will measure c…
Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Beyond the heel: Whole-Leg training may ease achilles tendon pain
Symptom relief OngoingThis trial tests whether a rehabilitation program that exercises the entire leg — from foot to hip — can improve balance, reduce pain, and restore function better than standard tendon-focused exercises in people with chronic Achilles tendinopathy. Fifty adults aged 18 to 45 with …
Sponsor: May University in Cairo • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
One-Shot knee injection could ease arthritis pain
Symptom relief OngoingThis study tests a single injection called 4P004 for people with knee osteoarthritis and synovitis (inflammation). About 129 adults aged 40-80 will receive either the injection or a placebo. The goal is to see if it reduces daily knee pain and improves function over 12 weeks.
Phase 2 • Sponsor: 4Moving Biotech • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Which Non-Surgical treatment eases shoulder calcium pain best?
Symptom relief PausedThis study compares three non-surgical treatments—exercise therapy, shockwave therapy, and ultrasound-guided irrigation—against a wait-and-see approach for people with painful calcium deposits in the shoulder. About 116 participants with confirmed calcific tendinopathy will be ra…
Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Shockwave or laser: which zaps plantar fasciitis pain best?
Symptom relief OngoingThis study compares two non-invasive treatments—extracorporeal shock wave therapy and high-intensity laser therapy—for chronic plantar fasciitis, a common cause of heel pain. Sixty adults will receive one of the treatments plus standard physical therapy. Researchers will measure …
Sponsor: Ibrahim Abuomar Fadulaalhq Alramadhani • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Could a magnetic helmet ease bladder pain? new study investigates
Symptom relief OngoingThis study tests whether a non-invasive magnetic brain stimulation technique, called rTMS, can reduce pain in women with interstitial cystitis or bladder pain syndrome. The treatment targets brain areas that control pelvic floor muscles, aiming to lower pain by improving how the …
Sponsor: University of Southern California • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
VR therapy could speed up wrist recovery after fractures
Symptom relief OngoingThis study tests whether using virtual reality and action observation therapy during the time a wrist or hand is in a cast can improve recovery. Participants watch first-person videos of hand movements through a VR headset and then practice those movements. The goal is to prevent…
Sponsor: University of Malaga • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New study tests which therapy works best for heel pain
Symptom relief By invitation onlyThis study compares two treatments for plantar fasciitis, a common cause of heel pain. About 56 adults with heel pain for at least 6 weeks will receive either instrument-assisted soft tissue mobilization or manual massage. Researchers will measure pain, daily function, and walkin…
Sponsor: Ibadat International University, Islamabad • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New nerve zapping technique could ease stubborn shoulder pain
Symptom relief OngoingThis study looks at whether a treatment called pulsed radiofrequency (PRF) applied to a key shoulder nerve can help people with long-lasting shoulder pain that hasn't improved with standard treatments like painkillers or physical therapy. The study involves 60 adults with chronic…
Sponsor: Gülçin Babaoğlu • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Can an online course keep arthritis patients working?
Symptom relief OngoingThis study tests an online program designed to help people with inflammatory arthritis remain employed. The program includes eLearning modules, group video sessions, and consultations with an occupational therapist and vocational counselor. About 528 participants from three Canad…
Sponsor: University of British Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Can exercise ease pain after radiation for bone cancer? small trial aims to find out
Symptom relief By invitation onlyThis study tests whether a structured, supervised exercise program is safe and feasible for people with painful non-spine bone metastases who have just had palliative radiotherapy. Twenty participants will follow an 8-week exercise plan plus a short maintenance period. Researcher…
Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Lupus fatigue fight: coaching shows promise
Symptom relief OngoingThis study tests whether personalized coaching on physical activity and nutrition can reduce fatigue in people with lupus. 200 participants are split into two groups: one gets coaching on exercise and diet, the other gets general lupus education. The goal is to see if the coachin…
Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Tiny beads aim to quiet arthritic knees without surgery
Symptom relief OngoingThis study tests a new procedure called genicular artery embolization using SakuraBead, a dissolvable bead that blocks small blood vessels in the knee to reduce pain. It involves 89 adults aged 40-79 with moderate to severe knee osteoarthritis that hasn't improved with standard t…
Sponsor: CrannMed • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Can remote rehab help lung patients breathe easier?
Symptom relief OngoingThis pilot study tests whether home-based or video-supervised exercise programs are acceptable and helpful for people with chronic lung diseases like IPF, sarcoidosis, bronchiectasis, asthma, and other interstitial lung diseases. Fifty participants will be randomly assigned to on…
Sponsor: Copenhagen University Hospital, Hvidovre • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New combo treatment aims to quiet jaw pain for TMD sufferers
Symptom relief OngoingThis study tests whether wearing a custom mouth splint and getting a granisetron injection into the jaw muscle reduces pain from temporomandibular disorders (TMD) better than the splint alone or with lidocaine. About 48 adults with jaw muscle pain will be followed for 6 months. T…
Phase 4 • Sponsor: Mansoura University • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Sound waves vs. bone pain: can ultrasound replace radiation?
Symptom relief OngoingThis study tests whether MR-guided focused ultrasound (MR-HIFU), alone or with standard radiotherapy, can better relieve pain from bone metastases than radiotherapy alone. About 216 adults with painful bone lesions will be randomly assigned to one of three groups. The goal is to …
Sponsor: UMC Utrecht • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Poop pills could ease stomach troubles for scleroderma patients
Symptom relief OngoingThis study tests whether fecal microbiota transplantation (FMT) – giving healthy donor stool in capsules – can safely reduce chronic diarrhea in people with systemic sclerosis. Twenty adults with scleroderma and persistent diarrhea will receive either FMT or a placebo. The main g…
Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Yoga coaching shows promise for lupus pain in small trial
Symptom relief OngoingThis study tests a personalized yoga coaching program for people with lupus who have chronic pain. Fifteen participants work with a coach to create a yoga practice that fits their needs and limits. The goal is to see if the program is feasible and if it helps reduce pain. It is a…
Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
New study tests Self-Management as a Drug-Free fix for hip pain
Symptom relief OngoingThis study tests whether a self-management program led by a physiotherapist can reduce pain and improve function in people with greater trochanteric pain syndrome (chronic hip pain). 110 adults aged 18-70 with hip pain for over 3 months will be randomly assigned to either the sel…
Sponsor: Oslo University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Vitamin c IV may curb blood loss in hysterectomy
Symptom relief By invitation onlyThis study tests whether giving vitamin C through an IV before and during a hysterectomy can reduce blood loss. Forty women with fibroids or adenomyosis will receive either vitamin C or a placebo. Researchers will measure blood loss during surgery and check if vitamin C helps mai…
Sponsor: Queen Savang Vadhana Memorial Hospital, Thailand • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Jaw surgery showdown: which TMJ fix works best?
Symptom relief By invitation onlyThis study looks back at 65 adults who had one of two surgeries for a painful jaw joint condition (TMJ disc displacement). The goal is to see which surgery better improves mouth opening, reduces pain, and helps the jaw work better. Researchers also check recovery speed, side effe…
Sponsor: Karolinska Institutet • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Exercise as medicine? new study tests High-Intensity workouts for rheumatoid arthritis
Symptom relief OngoingThis study looks at whether a 12-week program of high-intensity interval exercise can improve heart function, reduce inflammation, and boost quality of life in people with rheumatoid arthritis. 87 adults with stable, low-to-moderate disease activity will take part. The program in…
Sponsor: Vastra Gotaland Region • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
RA injection study pulled before it even started
Symptom relief CancelledThis study aimed to test the safety of a new drug called F8IL10, given as a joint injection every 4 weeks for 8 weeks, in people with rheumatoid arthritis who still have joint flares despite standard treatments. The goal was to find the safest dose. However, the study was withdra…
Phase 1 • Sponsor: Philogen S.p.A. • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Exercise as a potential remedy for chronic bladder pain?
Symptom relief CancelledThis study planned to see if a 6-week supervised exercise program could reduce symptoms of interstitial cystitis (painful bladder syndrome) and improve quality of life in adult women. Participants would have walked and done light strength training three times a week. However, the…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Learning to live better: education program aims to ease rheumatoid arthritis struggles
Symptom relief OngoingThis study tests whether a 6-month patient education program can improve quality of life for people with rheumatoid arthritis. The program covers topics like understanding the disease, monitoring symptoms, treatment options, nutrition, and stress management. Researchers will comp…
Sponsor: Hassan II University • Aim: Symptom relief
Last updated Jun 26, 2026 15:58 UTC
-
Could a home brain stimulator ease arthritis pain?
Symptom relief By invitation onlyThis study tests whether a gentle electrical brain stimulation device, used at home, can reduce chronic pain in people with rheumatoid arthritis whose inflammation is already well-controlled. Thirty-four participants will either receive real or sham stimulation over several sessi…
Sponsor: Federal University of Rio Grande do Sul • Aim: Symptom relief
Last updated Jun 26, 2026 14:52 UTC
-
Scientists track families to uncover Cancer's hidden causes
Knowledge-focused OngoingThis study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Rare bone cancer study hunts for hidden genetic triggers
Knowledge-focused OngoingThis study aims to find genetic changes that may cause sporadic chordoma, a rare bone cancer. Researchers will collect saliva and medical records from 188 patients across the U.S. and Canada who are the only ones in their family with chordoma. No treatment is given; the goal is t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New brain scan may predict chemo brain in young leukemia patients
Knowledge-focused PausedThis study tests a quick, non-invasive brain scan called Magnetic Resonance Fingerprinting (MRF) in children and young adults with acute leukemia. The goal is to see if the scan can detect early brain changes caused by chemotherapy. Participants also take a fun, game-like memory …
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New scan could improve how we monitor bone metastases in breast cancer
Knowledge-focused OngoingThis phase 2 trial is testing whether a special type of PET/CT scan (FDG-PET/CT) can better measure how breast cancer that has spread to the bones responds to treatment. The study involves 138 participants with hormone receptor-positive metastatic breast cancer that is mostly in …
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Lupus care under the microscope: new registry tracks Real-World treatment in kazakhstan
Knowledge-focused OngoingThis study is a registry that will follow about 500 adults with lupus (SLE) in Kazakhstan to see how the disease behaves and how doctors treat it in everyday practice. Researchers will look at disease activity, organ damage, and which medications are used. No new treatments are b…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Registry maps the return of a stubborn heart condition
Knowledge-focused OngoingResearchers are building a registry to follow adults with recurrent pericarditis, a condition where inflammation around the heart keeps coming back. The registry collects information over time on how often flare-ups happen, what treatments patients receive, and whether they are h…
Sponsor: Eurasian Association of Therapists • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Shoulder surgery secrets: anchor angle may determine healing success
Knowledge-focused OngoingThis study looks at how the position and angle of surgical anchors used in rotator cuff repair affect cyst formation and tendon healing. Researchers will use MRI scans to measure cyst volume and assess tendon recovery in 70 adults aged 18–70 undergoing primary arthroscopic repair…
Sponsor: Fatih Sultan Mehmet Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Choice or fixed? study tests how to get better data from young cancer patients
Knowledge-focused OngoingThis study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…
Early phase 1 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New blood test could spot cancer return after transplant
Knowledge-focused OngoingThis study is testing a new blood test called AlloHeme that measures how much of a patient's own cells remain after a bone marrow transplant. The goal is to see if this test can predict whether the cancer (acute leukemia or myelodysplastic syndrome) will come back. About 307 adul…
Sponsor: CareDx • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Massive medicare study aims to improve joint replacement safety
Knowledge-focused OngoingThis study looks at records from over 500,000 Medicare beneficiaries with rheumatoid arthritis or ankylosing spondylitis who had major orthopedic procedures like joint replacements or spine surgery between 1999 and 2015. Researchers want to understand how often complications happ…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Will a new drug form work the same? study tests two versions of SKI-O-703
Knowledge-focused OngoingThis study tests whether two different capsule forms of the experimental drug SKI-O-703 are absorbed similarly in the body. About 48 healthy adults (Korean and Caucasian) will take a single dose of each form on separate days, with blood samples taken to compare drug levels. The r…
Phase 1 • Sponsor: Oscotec Inc. • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Massive psoriasis registry tracks drug safety over years
Knowledge-focused OngoingThis study is a large registry that follows nearly 16,000 people with psoriasis to monitor the long-term safety of several treatments, including biologic drugs like infliximab and ustekinumab. Participants receive their usual care while researchers track side effects, disease act…
Sponsor: Janssen Scientific Affairs, LLC • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Psoriatic arthritis drug showdown: which treatment do patients stick with?
Knowledge-focused OngoingThis study follows over 1,300 people with psoriatic arthritis who are starting either guselkumab (Tremfya) or an IL-17 inhibitor as part of their routine care. Researchers will track how long patients continue each treatment and monitor joint swelling and tenderness. The goal is …
Sponsor: Janssen Pharmaceutica N.V., Belgium • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Can young sarcoma survivors fully recover? a new study investigates
Knowledge-focused OngoingThis study looks at children, teens, and young adults who finished treatment for bone or soft tissue sarcoma in the lower leg or thigh 1 to 5 years ago. It measures muscle size, body composition, strength, mobility, and quality of life to see if they have lasting physical limitat…
Sponsor: Technical University of Munich • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Study reveals: sticking to sarcoidosis meds may improve outcomes
Knowledge-focused OngoingThis study looks at how well people with sarcoidosis take their prescribed medicines and whether that affects their disease. Researchers will follow 150 adults in Maryland and D.C. for one year, tracking lung function, symptoms, and hospital visits. The goal is to find ways to he…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a biologic drug tame juvenile arthritis in kids?
Knowledge-focused CancelledThis study follows children aged 6 to 17 with active juvenile enthesitis-related or psoriatic arthritis who are being treated with secukinumab. Researchers will track how long children stay on the drug, how much their symptoms improve, and whether they achieve remission. The goal…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Can a smartphone app help teens with lupus and depression stay on track?
Knowledge-focused OngoingThis study aims to understand how depression symptoms, like loss of interest, may make it harder for teens and young adults with lupus to keep up with their medical care. Researchers will also test a mobile health app designed to provide education and connect users to their care …
Sponsor: Montefiore Medical Center • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Simple tests could revolutionize chronic pain diagnosis
Knowledge-focused OngoingThis study aims to improve how doctors diagnose and treat chronic muscle and joint pain by using simple questionnaires and pain sensitivity tests. Researchers will study 250 adults with conditions like osteoarthritis, fibromyalgia, chronic low back pain, or inflammatory arthritis…
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Can skin elasticity predict dupuytren recurrence?
Knowledge-focused OngoingThis study looks at how the skin on the palm of the hand is involved in Dupuytren disease, a condition that causes fingers to bend inward. Researchers will measure skin elasticity with a suction device, use ultrasound to see the tissue beneath, and take a small skin sample during…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Digital diary aims to decode painful flares in spine condition
Knowledge-focused OngoingThis study investigates how people with axial spondyloarthritis (axSpA) experience sudden worsening of symptoms, known as flares. Over 12 months, 40 participants use a digital diary to track symptoms, diet, lifestyle, and self-management strategies, and provide blood samples duri…
Sponsor: Royal United Hospitals Bath NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Marfan syndrome in kids: new study looks beyond the physical symptoms
Knowledge-focused OngoingThis study observes 80 children with Marfan syndrome to understand how the condition impacts their quality of life, self-image, and ability to manage their health. Participants fill out questionnaires about their well-being and medication habits. The goal is to identify who might…
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Blood test may predict aneurysm surgery need in marfan patients
Knowledge-focused OngoingThis study looks for biological markers in the blood and tissue of adults with Marfan syndrome that could signal when an aortic aneurysm is dangerous enough to require surgery. Researchers will compare three groups of Marfan patients: those without aortic aneurysms, those with st…
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Math formula could help surgeons cut bone graft waste in tumor surgery
Knowledge-focused OngoingThis study tests whether a simple mathematical formula, applied to routine CT scans, can accurately predict the size of a bone defect that will be created during surgery to remove a bone tumor. Accurate prediction could help surgeons select the right-sized donor bone graft before…
Sponsor: Sakarya University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a blood test predict lupus flares? new study aims to find out
Knowledge-focused OngoingThis study follows 25 adults with inactive lupus to see if blood samples can predict when a flare will happen. Researchers will analyze genes and other molecules to find patterns linked to flare risk. The goal is to develop tools that help doctors personalize treatment and preven…
Phase 3 • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Cushing's disease study in western france withdrawn before starting
Knowledge-focused CancelledThis study was designed to look back at the health of people with Cushing's disease in Western France between 1990 and 2015. The goal was to find out how many patients went into remission and how many had their disease come back after their first surgery. However, the study was w…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Do blood transfusions help at the end of life? a study asks patients and staff
Knowledge-focused OngoingThis study looks at how patients with advanced blood cancers (like acute myeloid leukemia) who are not eligible for a cure, along with their nurses and doctors, feel about the benefits of blood transfusions. Researchers will give questionnaires before each transfusion to compare …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Study aims to see if patient diaries match insurance data
Knowledge-focused CancelledThis study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Researchers hunt for clues to prevent dangerous clots in rare blood cancer
Knowledge-focused OngoingThis study watches 242 adults with high-risk polycythemia vera (a rare blood cancer that thickens the blood) who have already had a blood clot. Researchers track health data like blood pressure, weight, and lab tests to see which factors best predict future clots. The goal is to …
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study tracks how leukemia drug works outside the lab
Knowledge-focused OngoingThis study follows 201 adults with chronic myeloid leukemia who are taking asciminib (Scemblix) as a third or later treatment option. Researchers want to see how long patients stay on the drug and how well it controls their cancer in real-world settings. The goal is to gather pra…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Skin cells may reveal secrets of deadly aortic bulges
Knowledge-focused By invitation onlyThis study looks at skin cells (fibroblasts) from people with Marfan syndrome and other genetic conditions that cause thoracic aortic aneurysms (a bulging of the main artery in the chest). Researchers want to find out how these cells behave differently and what genes or proteins …
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Brain scans may predict who gets long-term pain from arthritis
Knowledge-focused OngoingThis study looks at why some people with early rheumatoid arthritis develop long-lasting chronic pain while others do not. Researchers will use pain sensitivity tests and brain scans to find clues. The goal is to better understand the transition from acute to chronic pain, which …
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
700 women followed for over a decade to see which fibroid treatments last longest
Knowledge-focused OngoingThis study follows about 700 women for up to 12 years after they had a uterine-sparing fibroid treatment, such as myomectomy or uterine artery embolization. Researchers want to see how long these treatments last before another procedure is needed, and how women's symptoms and qua…
Sponsor: Henry Ford Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Fitness check may guide better leukemia care for seniors
Knowledge-focused OngoingThis study looks back at medical records of 725 older adults (over 65) with acute myeloid leukemia (AML). Researchers want to see if using a special 'fitness' score to choose treatment leads to longer survival. No new treatments are given; the goal is to learn which treatment app…
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Bone metastasis database study aims to improve patient quality of life
Knowledge-focused CancelledThis study collects medical information from patients whose cancer has spread to the bone. The goal is to learn more about how cancer affects bones and how to prevent complications like fractures and pain. No extra tests or visits are needed—just data from regular care. The study…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Does an extra knee ligament procedure lead to arthritis later?
Knowledge-focused By invitation onlyThis study follows 510 people who had ACL knee reconstruction surgery, with or without an extra procedure called LET, about 10 years ago. Researchers want to see if adding LET increases the chance of developing knee osteoarthritis. Participants will get X-rays and answer question…
Sponsor: Western University, Canada • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Massive hip replacement study seeks best stem length
Knowledge-focused By invitation onlyThis study looks at over 110,000 people who had hip replacement surgery to see if a longer or shorter hip stem works better. It compares death rates, how often the hip implant needs to be replaced, and patient-reported pain and function. The goal is to find out which stem length …
Sponsor: JointResearch • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New registry aims to unlock safer pregnancies for women with autoimmune conditions
Knowledge-focused By invitation onlyThis registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Tiny study peers inside finger joints to unlock RA bone erosion secrets
Knowledge-focused OngoingThis study looks at bone erosions in the finger joints of 9 people with rheumatoid arthritis. Researchers use advanced imaging and tissue analysis to see tiny blood vessels and bone structure. The goal is to better understand how joint damage happens, which could lead to better m…
Sponsor: University of Aarhus • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New hip cup under observation: will it last?
Knowledge-focused OngoingThis study is observing 60 people who received a special hip replacement cup (Plasmafit Revision Structan) during routine surgery. Researchers are checking how well the cup works and how long it lasts by tracking hip function and any need for repeat surgery. No new treatment is b…
Sponsor: Aesculap AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scleroderma biomarker study pulled before start
Knowledge-focused CancelledThis study planned to collect extra blood and urine samples from scleroderma patients during their regular check-ups to find biological markers that could predict if their disease would get worse over the next 10 years. The goal was to improve treatment decisions and identify the…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to uncover hidden cancer clues in autoimmune disease
Knowledge-focused OngoingThis study examines blood samples from 50 people with dermatomyositis, an autoimmune disease that raises the risk of cancer. Researchers are looking for new antibodies and immune molecules that might signal which patients are more likely to develop cancer. The goal is to improve …
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
450 babies help scientists unlock secrets of healthy eating
Knowledge-focused OngoingThis study follows 450 infants and their families from birth to age 12 to learn how a child's biology and home environment work together to shape eating habits and growth. Researchers collect samples, measurements, and surveys at regular visits. The goal is to understand what inf…
Sponsor: University of Illinois at Urbana-Champaign • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Fibroid treatment showdown: which procedure stands the test of time?
Knowledge-focused OngoingThis nationwide registry follows 578 women with uterine fibroids who choose either radiofrequency ablation (Acessa) or myomectomy. Researchers track symptom changes, quality of life, and need for repeat treatment over three years. The goal is to understand which procedure provide…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Massive study of 190,000 workers to uncover hidden radiation risks
Knowledge-focused OngoingThis study follows about 190,000 Korean radiation workers to see if low-dose radiation exposure over time increases the risk of cancer and other diseases. Researchers will link national health records to track health outcomes. The goal is to better understand the long-term effect…
Sponsor: Korea Institute of Radiological & Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Could your phone camera replace blood tests? new study explores
Knowledge-focused OngoingThis study follows 60 people with lower-risk myelodysplastic neoplasms (MDS) who need regular red blood cell transfusions. Over 6 months, participants use a smartphone app to answer weekly quality-of-life questions and take photos of their fingernails or eyelids. Researchers aim …
Sponsor: University of Leipzig • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study observes patients getting nasal stem cell therapy for brain conditions
Knowledge-focused By invitation onlyThis observational study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, multiple sclerosis, or Alzheimer's who are already receiving intranasal MuSE stem cell or exosome therapy as part of their routine care. Researchers track safety and…
Sponsor: Healing Hope International • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Pain mystery: why teens with quiet arthritis still hurt?
Knowledge-focused CancelledThis study planned to find out how often teenagers with juvenile idiopathic arthritis experience chronic pain, especially when their arthritis seems quiet or mild. Researchers wanted to measure pain intensity and how it affects daily life, school, sleep, and social activities. Th…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
French launch largest study of rare tumor disease
Knowledge-focused OngoingThis study aims to create the largest French database of people diagnosed with aggressive fibromatosis, a rare tumor that grows in connective tissue. Researchers will collect tissue samples, medical history, and genetic information from 628 participants across France. The goal is…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Rare disease pregnancy study pulled before it began
Knowledge-focused CancelledThis study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Resident's journey to master scarless hysterectomy under the microscope
Knowledge-focused OngoingThis study watches a single gynecology resident as they learn to perform a hysterectomy through the vagina using a special camera, leaving no belly scars. The goal is to see how quickly the resident improves, measuring surgery time and any complications. Nineteen women with benig…
Sponsor: Cukurova University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
CAR-T therapy patients monitored for years in new safety study
Knowledge-focused By invitation onlyThis study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…
Sponsor: AvenCell Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
15-Year safety check for caribou cell therapy patients
Knowledge-focused By invitation onlyThis study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…
Sponsor: Caribou Biosciences, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Study on COVID-19 and blood cancer connection pulled before starting
Knowledge-focused CancelledThis study was designed to learn how the protein calprotectin might change blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare cells from patients and healthy donors in the lab. However, the study was withdrawn before any parti…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New national registry aims to improve care for rare genetic polyposis syndromes
Knowledge-focused OngoingThis study is a national registry collecting data from 1500 people with familial adenomatous polyposis (FAP) and related conditions across 28 Italian centers. It aims to better understand how these diseases progress, how they are currently managed, and what factors influence outc…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Fatty liver and psoriasis study pulled before it started
Knowledge-focused CancelledThis study aimed to understand the link between non-alcoholic fatty liver disease (NAFLD) and psoriatic disease (psoriasis and psoriatic arthritis) in overweight adults. Researchers planned to use the drug guselkumab (Tremfya) to see if it improved both conditions. However, the t…
Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
500 patients join study to unravel recurrent heart inflammation
Knowledge-focused OngoingThis study follows 500 children and adults with recurrent pericarditis (repeated inflammation of the heart lining) to better understand the disease. Researchers will track which treatments patients use, how the disease affects quality of life, and the economic costs. The goal is …
Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Scientists hunt for hidden genes behind aortic aneurysms
Knowledge-focused OngoingThis study aims to uncover the genetic roots of aortic aneurysms and valve disease by analyzing tissue and blood samples from 3,000 participants. Researchers will look for new disease-causing genes and factors that affect disease severity. The goal is to build a biorepository to …
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Alaska fibroid holistic trial pulled before it began
Knowledge-focused CancelledThis study planned to test holistic medicine—like counseling and group talks—for unmarried women with uterine fibroids living on Tribal Lands or in Alaska. It aimed to see if these non-clinical approaches could help, but the trial was withdrawn before any participants joined. No …
Sponsor: Virtual Tribunal Monastery • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Lupus heart risk: new study seeks better prediction tools
Knowledge-focused OngoingThis study looks at 500 adults with lupus to see if certain immune markers can better predict who will develop heart disease. Participants give blood samples, have ultrasound scans of their neck arteries, and fill out diet and exercise questionnaires. The goal is to improve how d…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can a heart scan save lives in rheumatoid arthritis? major study aims to find out
Knowledge-focused By invitation onlyThis study will use advanced heart scans (coronary CT angiography) on 4,000 people with rheumatoid arthritis aged 50-75. The goal is to better understand why people with this condition have higher risks of heart attacks, strokes, and lung problems. Researchers will track particip…
Sponsor: Ellen Margrethe Hauge • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Rare bone tumor under the microscope: can we predict its behavior?
Knowledge-focused OngoingThis study gathers information from 77 Italian patients with a rare, low-grade bone tumor called clear cell chondrosarcoma. Researchers will review medical records, imaging, and tissue samples to find patterns that might predict whether the tumor will come back or spread. The goa…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Fibroid surgery may change uterine blood flow – new study investigates
Knowledge-focused By invitation onlyThis study looks at whether surgically removing uterine fibroids (myomectomy) changes blood flow in the main uterine artery. Researchers will use Doppler ultrasound to measure blood flow before and about 40 days after surgery in 70 premenopausal women. The goal is to provide new …
Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
120,000-Person study hopes to crack the code of chronic illness
Knowledge-focused PausedThis observational study plans to enroll 120,000 people with various chronic diseases like pancreatitis, diabetes, and arthritis. Researchers will collect blood samples and health data to study how genetics and lifestyle affect disease progression. The goal is to find common dise…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Bone cancer implant infections under the microscope
Knowledge-focused By invitation onlyThis study looks at why people with bone cancer (skeletal sarcoma) get more infections after joint replacement surgery than those with arthritis. Researchers will collect tissue and blood samples from 40 patients to compare immune and bacterial factors. The goal is to understand …
Sponsor: Vastra Gotaland Region • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Promising sarcoma combo study pulled before starting
Knowledge-focused CancelledThis study was designed for adults with certain types of soft tissue sarcoma that have specific immune cell clusters (TLS) in their tumors. Participants would have received pembrolizumab (immunotherapy) with or without olaparib (a DNA repair blocker) before surgery, followed by m…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Can a smartphone app cut down doctor visits for arthritis patients?
Knowledge-focused OngoingThis study tests whether a smartphone app can help people with psoriatic arthritis manage their condition with fewer in-person doctor visits. About 278 adults who already use certain arthritis medications will use the app to report symptoms. Researchers will compare visit frequen…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
New study tests if help with housing, food, or transport can cut missed arthritis appointments
Knowledge-focused OngoingThis study looks at whether helping people with inflammatory arthritis address social needs—like food, housing, or transportation—can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have missed appointments in the past year wil…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Biopsy-Guided arthritis treatment: a step toward personalized care?
Knowledge-focused CancelledThis study aimed to see if analyzing joint tissue (synovial biopsies) could help doctors pick the best biologic drug for people with rheumatoid arthritis who had not responded to standard treatments. It planned to assign patients to either an anti-TNF or a JAK inhibitor based on …
Phase 3 • Sponsor: Abu Dhabi Stem Cells Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
1,598 RA patients enrolled in quest to personalize treatment
Knowledge-focused OngoingThis study follows 1,598 adults with rheumatoid arthritis (RA) over time to identify biological markers that can predict how well a patient will respond to a drug or whether they might have side effects. Researchers also aim to understand how the disease progresses and affects da…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Weighty questions: how obesity affects arthritis drug dosing
Knowledge-focused CancelledThis study aimed to understand how body weight influences the way etanercept works in obese adults and children with arthritis. Researchers planned to use blood samples and computer models to find the best dose for heavier patients. However, the study was withdrawn before enrolli…
Phase 1 • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Italian MPN patients share their stories in landmark Quality-of-Life study
Knowledge-focused OngoingThis study is collecting information on quality of life and symptoms from 572 Italian patients with certain types of blood cancers called myeloproliferative neoplasms (MPNs). Participants fill out questionnaires about how their disease and treatments affect their daily functionin…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Hair loss side effect under scrutiny in fibroid drug study
Knowledge-focused CancelledThis study was designed to track hair loss in women with uterine fibroids who are taking the medication Oriahnn. Researchers planned to follow about 1,600 women for up to 24 months, using questionnaires and scalp photos to see how common hair loss is, when it starts, and if it go…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:30 UTC
-
New study tracks shoulder health in wheelchair users to prevent future pain
Knowledge-focused OngoingThis study follows 75 manual wheelchair users with spinal cord injuries over 3 to 5 years to see when and why shoulder problems start. Researchers use yearly MRIs and motion tracking to link daily activities to shoulder damage. The goal is to find ways to prevent shoulder pain an…
Sponsor: The University of Texas Medical Branch, Galveston • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:53 UTC
-
New algorithm aims to catch ovarian damage early in young cancer survivors
Knowledge-focused CancelledThis study was designed to see if a new monitoring algorithm could detect early signs of ovarian damage in women and girls who had cancer treatment. Researchers planned to compare a group using the new algorithm with a group that received standard care. However, the study was wit…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:42 UTC
-
Biosimilar arthritis drug under Real-World watch
Knowledge-focused OngoingThis study follows 600 people with moderate to severe rheumatoid arthritis who are prescribed Tyenne, a biosimilar of tocilizumab. Researchers will track how long patients stay on the treatment over 12 months. The goal is to see how well the drug works in everyday medical practic…
Sponsor: Fresenius Kabi SwissBioSim GmbH • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:58 UTC
-
Scientists probe muscle secrets in rare connective tissue disorders
Knowledge-focused OngoingThis observational study looks at muscle strength, structure, and nerve function in people with Marfan syndrome or Ehlers-Danlos syndrome. Participants undergo a non-invasive muscle ultrasound and perform voluntary contractions while their muscle activity is recorded. The goal is…
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:50 UTC
-
New study tracks hidden health problems in cancer survivors
Knowledge-focused OngoingThis study follows 500 adults aged 18-65 who completed chemotherapy for certain cancers and are in remission. Researchers will check for 19 possible late side effects over 5 years, including heart, lung, and hormone problems. The goal is to catch these issues early and connect pa…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:33 UTC
-
Can your foot shape predict heel pain? new study investigates
Knowledge-focused By invitation onlyThis study compares foot measurements, daily steps, and footwear choices between 30 people with plantar fasciitis and healthy volunteers. The goal is to uncover structural and behavioral risk factors for this common cause of heel pain. Results may inform future prevention and ort…
Sponsor: Medipol University • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:15 UTC